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Preface 
 
I spent my Ph.D. research in Pharmacological Sciences in the 
laboratory of Neurobiology and Neuropharmacology of Aging and 
Neurodegeneration in the Department of Experimental and Applied 
Pharmacology of the University of Pavia. 
During my research, I focused both on diagnostic and molecular 
aspects of Alzheimer‟s disease (AD) with the aim to find a biomarker 
for the early detection and to understand the pathogenic mechanism 
underlying the disease. 
AD is a progressive neurodegenerative disorder characterized by 
irreversible cognitive and physical deterioration that commonly 
begins with loss of recent memory, follows by a progressive cognitive 
decline and finally dementia. The hallmark pathological lesions for 
the confirmatory diagnosis are amyloid plaques and neurofibrillary 
tangles together with synaptic loss. 
Due to the aging of the population, AD is a growing socioeconomic 
and public health problem because its incidence doubles every five 
years between 65 and 85 years of age and it has major consequences 
on the life of the patient and his/her caretaker and its cost is 
important. Actually, there is no cure for the disease because of an 
incomplete understanding of the events that lead to the selective 
neurodegeneration of AD brain. 
The degenerative process probably starts 20–30 years before the 
clinical onset of the disease and this clinical phase, between 
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prodromal and established AD, is defined mild cognitive impairment 
(MCI). One of the major goal of AD research in the present era is the 
prevention of the disease, which entails early detection before the 
onset of symptoms. For this reason MCI, the earliest clinically 
detectable phase of dementia and AD, has become a focus of clinical, 
epidemiologic, neuroimaging, biomarker, neuropathological, disease 
mechanism and clinical trials research. 
As reported in the first Chapter of this thesis we have identified that 
an altered conformation of a protein named p53, constitutively 
expressed to maintain genomic integrity, is a new predictive 
biological marker of transition from MCI to AD.  
In Part 1, the focus is on peculiar aspects of pharmacogenetic and 
pharmacogenomics research in aging and age-associated diseases to 
define novel targets for therapeutic interventions aimed to checkpoint 
proteins. In fact, aging in higher animals may be influenced by the 
balance of cell survival versus death, at least in part regulated by a 
fine timing of checkpoint proteins and preservation of DNA integrity 
and correct repair. p53 is one of this proteins, recently shown to be 
involved in aging and AD.  
In Part 2, using peripheral blood cells from MCI and AD patients, we 
describe a blood-based cytofluorimetric method for unfolded p53 
protein detection that predicts the progression to AD in preclinical 
patients with MCI two years before clinical diagnosis of AD was 
made and we discuss the potential of the test in diagnosing AD. 
In Part 3, I describe my recent results concerning the study of 
unfolded p53 as marker of progression from MCI to AD. In 
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particular, I confirm in a longitudinal study on an independent 
population of patients, that elevated levels of unfolded p53 may be 
considered as high risk factor for the conversion to AD.  
Moving from the need of a biological marker to improve diagnostic 
accuracy, the second Chapter of this thesis is focused on the study of 
the molecular mechanism underlying the pathogenesis of AD. 
Previously, we found that the exposure to nanomolar concentrations 
of the amyloid peptide (Aβ) was responsible for an increased content 
of unfolded p53 in fibroblasts from control subjects; for this reason 
we hypothesis that low amounts of soluble Aβ can induce early 
pathological changes at cellular level that may precede the 
amyloidogenic cascade. One of these changes is the induction of the 
unfolded state of p53, suggesting a putative link between the protein 
and soluble Aβ. 
By investigating what could be the contribution of a conformational 
change of p53 in the pathogenesis of AD, we defined for the first time 
a hierarchical scale of events driven by Aβ. 
In particular, in Part 1 we describe that Aβ induces the depletion of 
the homeodomain-interacting protein kinase-2 (HIPK2), an 
evolutionary conserved serine/threonine kinase whose activity is 
fundamental in maintaining wild-type p53 conformation and function, 
with subsequent abolishment of p53 transcriptional activity. We 
demonstrate that HIPK2 degradation driven by Aβ determines the loss 
of p53 transcriptional activity which, in turn, may contribute to AD 
pathogenesis leading to dysfunctional cells. 
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Starting from the discover of this novel amiloyd-based mechanism in 
AD, in Part 2 I highlight the potential relevance of HIPK2 as a new 
putative functional biomarker useful in addressing new therapeutic 
strategies against not only cancer but also important neurological 
conditions, such as AD. 
After the list of papers published as result of my Doctoral work, the 
last part of this thesis is an extension of my interest in other scientific 
themes. 
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Chapter I 
 
Unfolded p53: a new role as predictive biomarker of the 
progression from mild cognitive impairment to 
Alzheimer’s disease 
 
Introduction 
p53 protein is a 53 KDa transcription factor constitutively expressed 
in most cells and tissues. The gene encoding p53 is located on human 
chromosome 17p13.1 which is one of the most common sites for 
genetic alterations in human solid cancer, since it is mutated in more 
than 50% cancer cases worldwide [1]. By the early 1990s, data from 
the first p53 knockout mice provided evidence of the potent tumor 
suppressor action of wild-type p53 [2]; subsequent research clearly 
demonstrated that the transcription factor is a key controller in cell 
cycle and determines the fate of the cell in response to oncogenic and 
to other stresses to maintain genomic integrity. Thanks to its role p53 
has gained the name of “guardian of the genome” [3]. 
To achieve this goal p53 may use a wide spectrum of activities within 
numerous signalling pathways, such as its ability to function as 
transcription factor, by inducing or repressing different genes, as an 
enzyme, acting as exonuclease during DNA reparation and as a 
regulatory protein, among others. p53 oversees the correct 
implementation of processes and it intervenes only in case of 
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dangerous deviations from the proper cellular activity [4]. When the 
cell is exposed to critical conditions or undergoes damages p53 
arbitrates cell faith [5] (Figure 1). 
 
 
 
Figure 1: Exposure to multiple signals such as ionizing radiation, aberrant growth 
signals, chemotherapeutic drugs, ultraviolet light, hypoxia and oxidative stress 
induces p53 to accumulate in the nucleus to bind specific DNA target sequences and 
to activate or repress the transcription of genes participating in cell cycle control, in 
DNA repair and genes that induce cell death such as p21 and Bax, respectively. 
(Extracted from www.sigmaaldrich.com). 
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Rationale 
Our group has studied p53 in fibroblasts from aged controls and 
demented patients finding that with aging there is an increase in the 
expression of an unfolded protein state, which is more pronounced in 
AD patients and is not dependent on gene mutations [6]. As a result of 
such conformational change, p53 partially loses its activity and shows 
a significant impairment in its DNA binding and transcriptional 
capacity when cells are exposed to a noxious stimulus [6]. In fact, AD 
fibroblasts are less vulnerable to oxidative injury than fibroblasts 
from non-AD subjects. Following these observations 
conformationally altered p53 has been proposed as putative biomarker 
for early AD [6]. This altered conformation can be experimentally 
recognized by an antibody (clone PAb240), which made these cells 
distinct from those of controls recognizing a primary epitope cryptic 
in wild-type p53 [7].  
Recently, in cultured peripheral blood cells derived from AD patients 
we observed a detectable amount of unfolded p53, which made these 
cells distinct from those of controls and from patients affected by 
other form of dementia, suggesting that unfolded p53 could be used as 
a biomarker of the disease [8] (Figure 2). 
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Figure 2: Immunofluorescence (A) and flow-cytometric analysis of blood cells 
from controls (CTR) and AD patients (B). (A) In the micrograph AD m/l, the 
fluorescence intensity of mononuclear cells (monocytes and lymphocytes, m/l) is 
evident as compared to the very faint background of CTR sample; figure ADg also 
showed some non-specific red fluorescence from polymorphonuclear cells 
(granulocytes, g). (B) Panels (a–d) are histograms reporting the fluorescence due to 
unfolded p53 expression (FL-2) vs. the number of reacting cells (events).  
 
Before presenting p53 as marker of transition from MCI to AD, I will 
reflect on specific aspects of pharmacogenetics/pharmacogenomics of 
aging and age-associated diseases that involve p53. 
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Part 1. 
 
Unfolded p53 in the study of aging and age associated 
diseases from the perspective of 
pharmacogenetic/pharmacogenomics research 
 
Published on “Current Pharmaceutical Design” (2008), 14(26): 2665-
2671, as 
 
PHARMACOGENETICS AND PHARMAGENOMICS, 
TRENDS IN NORMAL AND PATHOLOGICAL AGING 
STUDIES: FOCUS ON p53 
 
Cristina Lanni, Marco Racchi, Daniela Uberti, Giuliano Mazzini, 
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and Stefano Govoni 
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ABSTRACT 
In spite of the fact that the aging organism is the result of complex 
life-long gene/environment interactions, making peculiar the 
susceptibility to diseases and the response to drugs, pharmacogenetics 
studies are largely neglected in the aged. Altered response to drugs, 
cardiovascular and metabolic alterations, cancer and dementia are 
among the age associated ailments. The latter two are the major 
contributors to illness burden for the aged. Aging, dementia and 
cancer share a critical set of altered cellular functions in the response 
to DNA damage, genotoxic stress, and other insults. Aging in higher 
animals may be influenced by the balance of cell survival versus 
death, a decision often governed by checkpoint proteins in dividing 
cells. The paper is mainly focused on one of such proteins, p53 which 
has been recently shown to be involved in aging and Alzheimer‟s 
disease (AD). Within this reference frame we studied p53 in aged 
controls and demented patients finding that with aging there is an 
increase of mutant like conformation state of p53 in peripheral blood 
cells, which is more pronounced in AD patients. As a result of such 
conformational change, p53 partially loses its activity and may 
become unable to properly activate an apoptotic program when cells 
are exposed to a noxious stimulus. Moreover we found that the 
tertiary structure of p53 and the sensitivity to p53-dependent 
apoptosis are affected by low concentrations of soluble beta amyloid, 
the peptide that accumulates in AD brain but also present in 
peripheral tissues. It is possible that p53 conformers may occur in the 
presence of misfolded molecules such as, but not limited to, beta 
12 
 
amyloid. In particular at neuronal level the altered function of cell 
cycle proteins may affect synaptic plasticity rather than cell 
duplication. 
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PHARMACOGENETICS AND PHARMACOGENOMICS: 
OPPORTUNITIES IN AGING STUDIES 
The terms pharmacogenomics and pharmacogenetics tend to be used 
interchangeably, and a precise consensus definition of either remains 
elusive. However, pharmacogenetics refers to the role of genetic 
variation affecting drug response or adverse reactions to drugs [1]. 
While, pharmacogenomics better fits the definition of the science 
dealing with the analysis of genome (DNA) and of its products (RNA 
and proteins), aimed to correlate genomic information to cell or tissue 
response in order to find new targets for therapy, to develop new 
drugs and to study the response to them (see Drug Information 
Association website at www.diahome.org). 
The aging organism is the result of complex life-long 
gene/environment interactions, making peculiar the susceptibility to 
diseases and the response to drugs. Nowadays, altered response to 
drugs, cardiovascular and metabolic alterations, cancer and dementia 
are among the age associated ailments. In this context, the shift from 
broad treatment strategies to more individually and genetically 
selected approaches would ensure that therapies would be both safer 
and more effective. In fact with an increased understanding about 
how genes and drugs interact, many patients could undergo a genetic 
test to predict their response and help ensure the medicine and dose is 
right at the first time. However, pharmacogenetic studies in aged 
patients are largely neglected, even if in elderly people 
pharmacokinetic and/or pharmacodynamic changes occur compared 
to younger people, increasing the variability of the response. Aging is 
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characterized by a progressive loss of functional capacities of most if 
not all organs, a reduction in homeostatic mechanisms and a response 
to receptor stimulation. Also, loss of water content and an increase of 
fat content in the body are reported. These changes have to be taken 
into consideration when the prescription of particular (cardiovascular 
or neuropsychiatric) drugs in elderly patients increases the risk of 
adverse drug reactions [2]. Pharmacodynamic changes in the elderly 
can result in greater, or sometimes even lesser, drug sensitivity than 
that seen in a younger individual. A greater drug sensitivity is 
particularly noticed with those drugs which act on the central nervous 
system, such as benzodiazepines [3]; on the other hand, β-adrenergic 
agents are an example of a reduction in responsiveness in elderly 
individuals [4]. Even if there is a general trend of greater 
pharmacodynamic sensitivity in the elderly, however, this is not 
universal, and these age-related changes must be investigated agent-
by-agent. Thus, inter-individual differences in drug response and 
adverse effects may be caused by variability in drug metabolism due 
to genetic polymorphisms, induction or inhibition of the metabolism 
by concomitant drug intake, environmental or physiological factors or 
pathological conditions. As an example, the metabolism of donepezil, 
a selective acetylcholinesterase inhibitor used in the treatment of 
Alzheimer‟s disease (AD), is dependent upon the genetic 
polymorphisms of the gene encoding CYP2D6, which has a large 
number of allelic variants, causing either absent, decreased or 
increased enzyme activity [5-6]. Varsaldi and coworkers [7] observed 
a large inter-individual variability in the concentration to dose ratio of 
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donepezil among AD patients and noted that this variability partially 
correlated with the CYP2D6 genotype, thus suggesting that genetic 
polymorphism of CYP2D6 influences the metabolism and therapeutic 
outcome of donepezil. 
Compared to pharmacogenetics, an abundant literature on 
pharmacogenomic studies is available even if not yet well organized. 
To date, pharmacogenomic studies are mainly focusing on many 
questions related to aging, concerning the research for aging genes, 
disease causing genes, longevity genes and are also pointing to 
identify susceptibility genes related to specific diseases, which allow 
health care providers to predict more accurately the risk of an 
individual of developing a specific disease [8-9]. A number of 
laboratories are making substantial and exciting progresses in the 
understanding of the genetics of aging and longevity; the principal 
aim of this studies are that these gene discoveries will lead to the 
identification of drug targets-drugs that would slow down the aging 
process and permit people to delay and perhaps escape age-associated 
diseases. Interestingly, by overviewing PubMed Citations from 1950 
to 2008, the choice of model organism for aging is represented by 
Homo sapiens. In fact, while we found many data about 
developmental biology from worms, flies, and mice, there is a paucity 
of detailed information on the pathophysiology of aging, particularly 
in worms and flies; in contrast, there is a vast literature on these and 
all other aspects of human biology, including remarkable progress in 
human genetics [10]. Aging and susceptibility to diseases associated 
with aging are likely to be influenced by thousands of genes [11-12]. 
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The vast amount of available literature generated in this field needs, 
however, a systematic revision and confirmation studies for the 
frequently contrasting results. Lacking genetic variations that 
predispose to diseases (so called “disease genes”) as well as having 
variations that confer disease resistance (so called “longevity-
enabling genes”) are probably both important to confer a remarkable 
survival advantage [13-14]. Conversely, defective functions of genes 
associated with longevity may influence premature neuronal survival 
[8]. 
About aging genes, the debate regarding the existance of genetic 
mutations actually able to either cause or accelerate aging is still 
open. Some researchers have proposed a genetically set biological 
clock which establishes when a species begins to age. Telomere 
length and/or telomerase function have been selected as time keeper 
candidates because of their potential role in regulating the number of 
cell divisions [15]. However, reduction in telomerase activity with 
older age might actually be a defensive measure against the increased 
potential for age-associated cancer. Another genetic defense against 
cancer is the p53 gene. Tyner and colleagues have noted an increase 
in p53 activity as a result of a deletion mutation in the first six exons 
of the p53 gene associated with cancer prevention but also accelerated 
aging [16]. In fact, by generating transgenic mice carrying this 
mutation they found that mutant p53 mice exhibit an early onset of 
phenotypes associated with aging (reduced longevity, osteoporosis, 
generalized organ atrophy and a diminished stress tolerance), thus 
suggesting that p53 has a role in regulating organismal aging [16]. 
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Among susceptibility genes, there are now numerous examples of 
genetic variations that substantially predispose to age-related disease 
(for example Alzheimer‟s disease and apolipoprotein E ε4). The 
apolipoprotein E (APOE) gene is the most prevalent risk factor for 
AD, especially in those subjects harboring the APOE-4 allele, 
whereas carriers of the APOE-2 allele might be protected against 
dementia [8, 17-18]. Because these variations are also associated with 
increased mortality risk, it is likely that centenarians do not have 
many of these predisposing variations [18-20]. Within this context, 
Schachter and colleagues found that the frequency of the 
apolipoprotein ε4 allele decreases markedly with advancing age, 
whereas, one of its counterparts, the ε2 allele, becomes more frequent 
with advanced age among Caucasians [18]. 
 
STRATEGIES FOR PHARMACOGENOMIC STUDIES 
Cardiovascular and metabolic alterations, cancer and dementia 
represent complex age-associated diseases with multiple gene 
variations. Within the context of complex diseases, two different 
approaches are at the base of pharmacogenomic studies: one relies on 
a wide-genome screening and the other is driven by a specific 
hypothesis. 
A genome-wide screening strategy underpins on the fact that, with the 
completion of the human genome project, single nucleotide 
polymorphisms (SNP) genotyping is being undertaken in a large 
number of pharmacogenomic studies to identify variants associated 
with responses to specific drugs. Throughout the human genome, 
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several types of genetic polymorphisms can be found, but among 
these, SNPs are the most common polymorphisms and the attention of 
researchers has been focused on these in the last years. Genome-wide 
association studies have emerged as an increasingly effective tool for 
identifying genetic contributions to complex diseases and represent 
the next frontier to further understand the underlying etiologic, 
biological, and pathologic mechanisms associated with chronic 
complex disorders. There have already been success stories for 
diseases such as diabetes mellitus [21]. Another recent example of 
wide-genome screening comes from the Framingham Heart Study 
(FHS) [22]. AD provides another good example of a complex age-
associated disease with multiple genetic etiologies, including specific 
sub-types inherited as autosomal dominant traits, as well as common 
forms related to the inheritance of susceptibility genes. By performing 
genome-wide associations, an expectation is that the multiple 
contributing loci (as in AD) can be identified simultaneously, and 
then integrated into pathways contributing to a pathogenetic process 
for which drugs can be identified [23-24]. There is now experimental 
and clinical trial evidence to support this prediction [21, 25-27]. 
Roses and coworkers described the design of high throughput disease-
association SNP studies in AD [28], by confirming, from this initial 
screen that, among others, APOE4 is genetically associated with AD. 
Another screening strategy based on the use of microarray technology 
was also adopted for a new molecular test for AD in blood 
plasma [29]. Despite the great impact and the variety of available 
information, the screening strategy in pharmacogenomic studies 
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shows to date limitations yet. Currently, costs limit the widespread 
use of pharmacogenomics. Execution of pharmacogenomic studies is 
dependent on many pieces of information: access to accurate clinical 
and demographic data, DNA samples from well designed studies, 
SNPs, genotyping technologies, informatics technologies to handle 
large quantities of data, statistical methodologies for data analysis and 
interpretation. In this regard, other limitations in the progress of 
pharmacogenomics include tools used for collecting, archiving, 
organizing and interpreting the huge amount of data generated in a 
pharmacogenomics study so that data from different experiments can 
be compared. 
Specific hypothesis driven studies represent another approach in 
pharmacogenomics. Differently from widegenome screening, the 
strategy is focused on the knowledge of well-known genes involved 
in specific diseases. Taking as example AD, functional genomics 
studies in AD revealed that age of onset, brain atrophy, cognitive 
decline, apoptosis, immune function and amyloid deposition are 
associated with AD-related genes. The genetic defects identified in 
AD during the past 25 years are represented by mutations in the 
amyloid precursor protein (APP) gene, on chromosome 21, in the 
presenilin 1 (PS1) gene, on chromosome 14, and in the presenilin 2 
(PS2) gene, on chromosome 1 [8, 30-31]. In addition, polymorphic 
variants of risk in more than 200 different genes can increase 
neuronal vulnerability to premature death [18], with APOE gene 
(19q13.2) as the most prevalent risk factor for AD. Thus, focusing the 
study on one of these genes is possible to understand its specific role 
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on specific events typical of AD. On the other hand, instead, all 
together, these genetic factors could interact in still unknown genetic 
networks leading to a cascade of events characterized by abnormal 
protein processing and misfolding with subsequent accumulation of 
abnormal proteins, excitotoxic reactions, oxidative stress, 
mitochondrial injury, synaptic loss and deficiencies in 
neurotransmitter function [8, 30, 32-33]. 
Pertaining to the context of aging, another example of hypothesis-
driven study is based on checkpoint control by specific proteins. 
Aging in higher animals may be influenced by the balance of cell 
survival versus death, a decision often governed by checkpoint 
proteins in dividing cells. One of such proteins is p53; in mammals, 
p53 loss increases tumorigenesis, while specific gain-of-function 
alleles reduce tumor incidence but accelerate aging, suggesting a 
trade-off between tumor surveillance and stem cell maintenance [34].  
 
p53: AGING AND CRITICAL DECISION ABOUT CELL FATE 
The transcriptional network of p53-responsive genes produces 
proteins able to interact with a large number of other signal 
transduction pathways in the cell. p53 protein can trigger the onset 
either of reversible or permanent growth arrest [35-37] or of apoptosis 
[38-39]. However, the mechanisms involved in the decision between 
these cellular responses are not well understood. Cell type, the 
presence of growth factors or oncogenes, the intensity of the stress 
signal, and the cellular level of p53 have been cited as important 
factors in determining a specific p53-induced response [40-42]. 
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Posttranslational modifications of the p53 gene have also been 
reported to influence the response observed [43]. For example, p53 
phosphorylation by different kinases in response to stress can select 
for arrest or apoptosis, suggesting the involvement of modifiers 
upstream of the p53 protein [43-44]. 
Once a cell has been damaged and the DNA damage response and 
p53 are activated, a complex signaling network is engaged to result in 
a long-term cell fate decision. Rodier and coworkers reported an 
intriguing scheme showing four options adopted in normal 
mammalian cells [34]. Activation of cell cycle checkpoints by p53 
leads to transient cell growth arrest [45]; p53 physically localizes to 
sites of DNA damage to promote repair [46] and simultaneously 
stimulates the transcription of direct effectors of the cell growth arrest 
(e.g. the cyclin-dependent kinase inhibitor p21) as well as effectors 
required for effcient DNA repair of complex lesions that require 
longer processing (e.g. GADD45) [47]. At this point, several potential 
cellular outcomes can occur, most of which are heavily influenced by 
the cell type as well as the severity of the DNA lesions: transient cell 
cycle arrest (when DNA damage is not severe), defective repair 
(resulting in mutation, such as chromosomal aberrations), cell death 
(apoptosis) or permanent cell cycle arrest (cellular senescence) [34]. 
Thus, p53 protects the genome by promoting the repair of potentially 
carcinogenic lesions in the DNA, thereby preventing mutations. In 
addition, p53 eliminates or arrests the proliferation of damaged or 
mutant cells by the processes of apoptosis and cellular senescence 
[48-49]. Loss of function in p53 is usually associated to many 
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common human cancers. Mutant p53 is almost always defective for 
sequence-specific DNA binding, and thus for transactivation of genes 
upregulated by the wild-type protein [50]. Interestingly, when p53 is 
mutated in non-dividing cells, such as neurons, a dysfunctions 
accumulation can occur; Yang and coworkers, in fact, demonstrated 
the existence of aberrant neurons in AD brain, by showing that 
neurodegeneration is correlated to neurons reentering a lethal cell 
cycle [51]. 
 
CONFORMATIONALLY ALTERED p53 IN AGED 
CONTROLS AND ALZHEIMER’S DISEASE PATIENTS 
We have studied p53 in aged controls and demented patients finding 
that with aging there is an increase of conformationally altered p53, 
which is more pronounced in AD patients, to the point that it has been 
proposed as a putative biomarker in the early stages of the disease 
[52-53]. As a result of such conformational change, p53 partially 
loses its activity and may become unable to properly activate an 
apoptotic program when cells are exposed to a noxious stimulus [52]. 
In this study we described and demonstrated an abnormal response of 
AD fibroblasts to an acute oxidative injury; in particular, fibroblasts 
from AD patients were found to be less vulnerable to the oxidative 
injury induced by H2O2 in comparison with fibroblasts from non-AD 
subjects. Fibroblasts from sporadic AD patients represent an 
important starting point in the research for novel biomarkers because 
of their various abnormalities in metabolic and biochemical 
processes, which reflect some of the events in AD brain [54-55]. 
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Furthermore, on the basis of immunoprecipitation studies with 
conformation-specific p53 antibodies (PAb1620 and PAb240), which 
discriminated folded vs unfolded p53 tertiary structure, we found that 
in fibroblasts from AD patients a significant amount of total p53 
assumes an unfolded tertiary structure; such alteration can 
compromise p53 response to an acute injury elicited by an excess of 
free radical production. Mutant p53 found in AD fibroblasts has been 
demonstrated to be independent from gene mutations on the basis of 
sequence analysis of the p53 gene, thus suggesting that one of the 
peripheral events associated to the disease is responsible for 
generating a conformationally altered p53 isoform [52]. In the attempt 
of investigating on the mechanism of such alteration, we assessed the 
contribution of APP metabolic products to the change in p53 
conformational state. We found that the exposure to nanomolar 
concentrations of betaamyloid (Aβ) 1-40 peptide induced the 
expression of an unfolded p53 protein isoform in fibroblasts derived 
from non-AD subjects [56]. These data suggest that the tertiary 
structure of p53 and the sensitivity to p53-dependent apoptosis are 
influenced by low concentrations of soluble Aβ. On this basis, we 
hypothesised that low amounts of soluble Aβ induce early 
pathological changes at cellular level that may precede the 
amyloidogenic cascade. One of these changes is the induction of a 
novel conformational state of p53. If low amounts of Aβ peptide, not 
resulting in cytotoxic effects, are responsible for p53 structure 
changes, it could be possible to consider the unfolded p53 both as an 
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agent partecipating to the early pathogenesis and as a specific marker 
of the early stage of AD. 
We then investigated the altered p53 isoform in more accessible cells, 
such as peripheral blood cells [53] to determine the frequency and the 
extent of this defect in AD patients and to explore the possibility to 
develop an assay to validate conformationally altered p53 as a 
putative peripheral marker of the disease. The identification of new 
biological markers, to date, can be greatly useful both to improve 
diagnostic accuracy and/or to monitor the efficacy of putative 
therapies, since the confirmatory diagnosis of AD is possible only 
post mortem, based on recognition and quantification of senile 
plaques and neurofibrillary tangles. Furthermore, we set up a rapid 
and easy flow-cytometric approach to identify the different expression 
of conformationally altered p53 between AD and non-AD subjects. 
Differently from other data in literature regarding the development of 
biomarkers for AD or in CSF [57-58] or in blood [59-60], the main 
advantage of our study was the development of a biological sample 
preparation procedure as well as of an analytical method that could 
permit a routine analysis. If this method should be confirmed in a 
larger population and further validated, it could be useful in 
improving the knowledge regarding the clinical diagnosis of AD, 
because we could have the possibility to recognize AD and non-AD 
cases, by starting from small blood volumes thus using a less invasive 
technique [53]. Interestingly, we observed that the expression of 
conformationally altered p53, both in controls and AD, is an age 
dependent event, while it is independent from the length of illness and 
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from the MMSE score; this linear correlation with age would suggest 
that its significance would be different within specific age interval 
segments. In order to determine the diagnostic performance of 
conformationally altered p53 as an AD marker, we worked out 
sensitivity and specificity within different age intervals and found that 
these values were more significant in subjects up to 70 years of age 
(sensitivity of 90% to discriminate AD patients from non demented 
aged individuals at a specificity value of 77%) compared with the 
corresponding values for individuals older than 70 years [53]. 
Although the age stratification is admittedly a post-hoc analysis it 
serves to indicate that the putative marker proposed appears to be 
more important in the younger patients, also considering that the 
positivity to p53 conformational mutant induced a calculated O.R. of 
29.2 for AD. The fact that the most significant differences are 
observed in the youngest patients indicate that the measurement of 
conformational mutant p53 may be usefully applied to detect AD at 
the early stages, perhaps applied to those patients falling in the ill 
defined category of mild cognitive impairment (MCI). Whether this 
expression of conformationally altered p53 will be suitable as an 
adjunctive diagnostic tool to predict the conversion from MCI to AD 
is under investigation. 
In addition, in order to better characterize the nature of this different 
expression between AD and control subjects, we also evaluated 
whether the expression of conformational mutant p53 showed a 
correlation with the APOE status. We recruited a population of 75 
patients with sporadic AD, 69 healthy age-matched controls (CTR) 
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(Table 1). Genomic DNA was extracted from peripheral leukocytes 
by proteinase K digestion and standard phenol/chlorophorm 
extraction procedure. The APOE gene polymorphisms (isoforms 
APOE ε2, APOE ε3, APOE ε4) were determined by Hha I restriction 
endonuclease digestion of PCR products, according to Hixson and 
Vernier [61]. After having determined APOE gene polimorphisms, 
we then divided this population in four groups, control subjects and 
AD patients with and without the ε4 allele, to establish if the presence 
of the ε4 allele might further affect the expression of mutant-like p53. 
The expression of mutant conformational p53 was independent from 
distribution of ε4 allele of APOE, thus highlighting that the presence 
of ε3/ε4 and ε4/ε4 genotypes was not linked to a higher expression of 
p53 conformational status (Fig. 1). AD patients without the ε4 allele 
showed a higher expression of mutant-like p53 compared to 
respective controls (percent of PAb positive cells, mean ± SD; control 
subjects without APOEε4: 22.8 ± 12.2; AD without APOEε4: 39.3 ± 
15.0; AD without APOEε4 versus respective control P < 0.0001). The 
comparison of the APOEε4 positive cases did not show a statistically 
significant difference between AD and the respective controls 
possibly because of the small size of the control sample (8 patients). 
On the other hand, complexively the p53 may be a marker useful in 
the ε4 negative younger patients (< 70 years). 
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AD  CTR  
 
N (M;F)  
 
75 (20;55)  
 
69 (35;34)  
 
mean age + SD  79 + 9  78 + 10  
 
L.O.I. (month)  53 + 26  
  
MMSE 14 + 6   28 + 1.6 
 
Table 1. Demographic and Clinical Variables of all the Subjects. N: number; M: 
male; F: female; L.O.I.: length of illness; MMSE: Mini-Mental State Examination. 
Data are expressed as mean + standard deviation. 
 
 
 
Figure 1: Correlation between the APOE status and conformational mutant 
p53. Box plot of the amount of conformational mutant p53 (%) expressed in 
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peripheral blood cells of all the subjects classified on the basis of their APOE 
genotypes. The figure is based on a rather innovative application in flow cytometry 
on peripheral blood cells. Venous blood samples were collected from a group of 75 
patients with sporadic AD and 69 healthy age-matched controls (CTR). Peripheral 
blood mononuclear cells were then analyzed for the expression of conformationally 
altered p53 with a flow cytometer. The APOE gene polymorphisms (isoforms 
APOE ε2, APOE ε3, APOE ε4) were determined by Hha I restriction endonuclease 
digestion of PCR products. Bonferoni multiple comparison test was used to 
compare values in different groups. Differences were considered significant when a 
p-value < 0.05 was attained. ***p < 0.001 vs control without ε4 allele. We 
previously published [53] the observation that the elevated conformationally altered 
p53 was specific for AD and not observed in other neurodegenerative diseases, such 
as Parkinson‟s disease, vascular dementia and sopranuclear palsy. 
 
CONCLUSIONS/PERSPECTIVES 
Aging in higher animals may be influenced by the balance of cell 
survival versus death, at least in part regulated by a fine timing of 
checkpoint proteins and preservation of DNA integrity and correct 
repair [62-63]. With our study we propose an example pointing to a 
peculiar aspect of pharmacogenetic/pharmacogenomics research in 
aging and age associated diseases, that is the possibility to define 
novel targets for therapeutic interventions aimed to chekpoint 
proteins. p53 has been recently shown to be involved in aging and 
AD. Recent evidence suggests that increased p53 activity can, at least 
under some circumstances, promote organismal aging [34]. We 
showed a link between AD pathology and conformationally altered 
p53 [52-54], by finding that with aging a higher increase of an 
unfolded state of p53 in AD patients compared to age-matched 
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controls occurs. What can be the contribution of a conformational 
change of a protein to the aging process is under investigation. We 
could also address the issue whether a generalization of this 
phenomenon within the context of the “gain and loss of function” of 
protein conformers will be possible. It is worth to underline that the 
observation that aging and AD interfere with proteins controlling the 
duplication and cell cycle, such as p53, is interesting and may lead to 
the speculation that, in senescent neurons, derangements in proteins 
commonly dealing with cell cycle control and apoptosis could affect 
neuronal plasticity and functioning rather then cell duplication.  
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ABSTRACT 
Mild cognitive impairment (MCI) is a syndrome defined as cognitive 
decline, but not sufficient to meet the criteria for any specific 
dementia. Although subjects with MCI may have an increased risk to 
develop AD, this clinical state encompasses several subtypes of 
cognitive dysfunction of different etiologies, none of which 
necessarily progresses to AD. The current inability of clinical criteria 
to accurately identify this at-risk group for AD development is 
fuelling the interest in biomarkers able to supplement clinical 
approaches. We recently described a blood-based cytofluorimetric 
method for conformationally altered p53 protein detection that allows 
the discrimination of AD patients from control subjects and patients 
affected by other dementias. 
The same protein also predicted progression to AD in preclinical 
patients with MCI two years before clinical diagnosis of AD was 
made. Herein, we describe these findings and discuss the potential of 
the test in diagnosing AD. 
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INTRODUCTION 
Alzheimer‟s disease (AD) is a progressive neurodegenerative disorder 
characterized by irreversible cognitive and physical deterioration. AD 
is the most common cause of dementia of the elderly population and 
its incidence doubles every five years between 65 and 85 years of age. 
It also represents a growing public health problem as life expectancy 
increases and the number of people with AD is expected to increase 
dramatically from approximately 24 million people in 2001 up to 81 
million worldwide by 2040 [1]. The treatment of AD remains a major 
challenge because of an incomplete understanding of the events that 
lead to the selective neurodegeneration typical of AD brains. In view 
of existing and emerging therapeutic compounds, the focus has 
increasingly shifted to accurate detection of the earliest phase of 
illness. 
The degenerative process in AD probably starts 20–30 years before 
the clinical onset of the disease [2]. This clinical phase, between 
prodromal and established AD, lies within the boundaries of the 
diagnosis of mild cognitive impairment (MCI), during which subjects 
have measurable cognitive deficits, but not sufficient to fulfill criteria 
for any specific dementia [3,4]. In particular, MCI subjects show the 
presence of subjective memory impairments, objective memory 
performance changes, and declining financial skills [5], whereas other 
cognitive functions and daily activities remain normal [6]. 
Although it is documented that subjects with MCI have an increased 
risk of AD, this clinical state encompasses several subtypes of 
cognitive dysfunction of varied etiologies, none of which necessarily 
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progresses to AD [7]. In particular, MCI subclassifications include an 
amnestic form (aMCI), characterized by isolated memory 
impairments, and one non-amnestic (naMCI) in which other cognitive 
functions rather than memory are mostly impaired [8]; within these 
groups, aMCI subjects showed 8.6-fold higher odds of developing 
AD [9]. Furthermore, it has been determined that patients suffering 
from aMCI progress to AD at a rate of 12 to 28% per year [3,10], 
whereas other MCI subjects improve, reverting to a normal level of 
cognitive functioning [11] and some die [12], thus underlining 
multiple etiologies for MCI. Hence, within this context, there is a 
need to reliably predict which patients with MCI will progress to AD. 
The current inability of clinical criteria to accurately identify this at-
risk group is fuelling the emerging interest in biomarkers to 
potentially supplement clinical approaches. 
Within this reference frame, we studied p53 in aged controls and 
demented patients finding that the conformational state of p53 protein 
in blood cells allows the differentiation of AD patients from control 
subjects and patients affected by other dementias. The notions about 
p53 come mainly from oncology. p53 has been described as a the 
guardian of the genome [13]. It is activated in response to certain 
stressful situations, inducing either cell cycle arrest and DNA repair 
or apoptosis [14]. The full-length p53 molecule comprises three major 
domains; the N terminus transactivation domain, the core DNA-
binding domain, that is stabilized by a Zn2+ atom coordinated by a 
histidine and four cysteines, and the C terminus tetramerization 
domain. p53 is mutated in about half of all human cancers, with 95% 
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of these mutations occurring in the core domain [15]. In particular, 
the core domain is endowed with high flexibility, and certain 
missense mutations inside this central domain can affect tertiary 
structure of the protein. 
Thermodynamic studies of p53 cancer mutations have identified three 
major phenotypes classified as: i) mutation affectingDNA contacts 
that have little impact on protein folding; ii) mutation disordering 
local structure leaving more than 85% of the protein in folded 
conformation; and iii) mutations globally denaturating the core 
domain, thus resulting in more than 50% of unfolded isoform [16–
19]. This third phenotype is recognized by PAb240 antibody, since its 
epitope is cryptic when p53 is in wild type conformation and becomes 
accessible only when the core domain is denatured. It should be 
stressed that conformational changes of p53 can also be due to 
posttranscriptional modifications in the absence of specific mutations 
[20–23]. 
Within this context, the presence of an altered unfolded p53 isoform 
was found enhanced in AD patients in comparison with control and 
other types of dementia [24]. Notably, the best sensitivity and 
specificity of this marker was observed at ages 70 years [24], 
suggesting the idea that unfolded p53 could also be detected in the 
early stage of the disease. 
On this basis, the purpose of our study was to further investigate 
whether conformationally altered p53 expression may be applied to 
those patients falling in the ill-defined category of MCI and in 
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particular to predict which subjects among MCI patients will progress 
to AD. 
 
MATERIALS AND METHODS 
Subjects 
Venous blood samples from healthy people and from patients affected 
by MCI and AD were obtained from Sant‟Orsola Hospital in Brescia, 
Italy. This population consisted in a group of 45 patients with 
sporadic AD, 45 healthy age-matched controls (CTR), and 28 patients 
with MCI (Table 1). 
The protocol of the study, including the follow-up visits, was 
approved by the Ethical Committee and a written consentwas 
obtained fromall subjects or, where appropriate, their caregivers. 
All the subjects were examined by a senior neurologist or geriatrician 
and diagnosis of dementiawas made according to DSM-IV and the 
NINCDS-ADRDA criteria. All MCI subjects met the original 
Petersen/Mayo criteria for MCI [3,7]. Dementia was diagnosed based 
upon interview, objective and neurological examination, cognitive 
evaluation, laboratory and radiological (CT scan) investigation. 
Cognitive statuswas quantified using the Mini Mental State 
Examination (MMSE). All AD patients fulfilled the criteria for 
probable AD [25] and were classified as “sporadic” on the basis that 
they lacked a familial history of the disease, as acquired from 
interviews with first degree relatives. Control subjects were aged 
individuals with no clinical signs of neurological or psychiatric 
diseases, mostly enrolled among spouses of the AD group of patients. 
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None of the subjects selected in this study was affected by neoplastic 
or autoimmune disease when the blood samples were taken. For each 
subject, the count of leukocytes was within the regular interval 
clinical frame. 
After two years from the recruitment, all 28 MCI subjects were 
recalled and examined by the geriatrician. The progression to AD was 
diagnosed based upon interview, objective and neurological 
examination, cognitive evaluation, laboratory and radiological (CT 
Scan) investigation. 
 
Flow cytometry 
Peripheral blood mononuclear cells (PBMC) were isolated by 
centrifugation on a Ficoll Hipaque density gradient from Na+/citrate 
samples (Eurobio, Italy) and fixed in 2% formaldehyde in PBS. 
Rinsed cells were permeabilized with 0.2% saponin in PBS solution 
and incubated in ice for 30 min with a primary monoclonal antibody 
recognizing unfolded p53 (clone PAb240; NeoMarkers, Fremont, 
CA) (4 μg/ml in PBS/1% BSA solution). In particular the PAb240 
antibody recognizes the epitope 211–217 aa inside the core domain, 
which is accessible only when the core domain is denatured and the 
protein assumes an unfolded tertiary structure, thus discriminating the 
so called “mutant-like” isoform [22]. Cells rinsed in PBS/1% BSA 
were incubated for 30 min in ice with a goat anti-mouse IgG antibody 
phycoerythrin (PE)-conjugated (DakoCytomation, Denmark; 1:40 in 
PBS/1% BSA). After rinsing, fewmicroliters of cell suspension were 
deposed on a glass slide and observed with a fluorescence microscope 
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Olympus BX51 with blue excitation (BP450–480 nm, DM 500, 
andbarrier filter 515 nm) equipped with a Camedia digital camera. 
Samples were observed at 40X magnification. Pictures were taken 
with the same instrumental setting. Orange-red fluorescence from AD 
positive cells was compared with the background fluorescence of 
control samples as a technical control of the experimental setting. The 
percentage of PAb240 positive cells was quantified by 
cytofluorimetric analysis. Cell suspension was analyzed with a flow 
cytometer Partec PASII (Partec, Germany). PBMC population was 
identified by forward and side angle scatter (FSC, SSC) and mutant 
p53 emission was detected in the FL-2 channel (535–580 band pass 
filter). For each sample, data from 20000 events were recorded in list 
mode, displayed on logarithmic scales and analyzed usingWinMDI 
2.8 software. 
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 CTR AD MCI 
N (M;F) 45 (20;25) 45 (9;36) 28 (5;23) 
mean age + SD 75 + 12.6 81 + 7.2 69 + 12.4 
L.O.I. (month)  52 + 23 19 + 6 
MMSE 28.4 + 1.6 14 + 5.5 27.3 + 2 
Genotype CTR AD MCI 
ε2/ε3 5 (11) 2 (4) 3 (10.7) 
ε3/ε3 35 (78) 25 (56) 17 (60.7) 
ε3/ε4 5 (11) 14 (31) 7 (25) 
ε2/ε4 0 0 1 (3.6) 
ε4/ε4 0  4 (9) 0 
 
Table 1: Demographic and clinical variables and genotype frequency of the 
APO-E polymorphisms of all the subjects. N: number; M: male; F: female; 
L.O.I.: length of illness; MMSE: Mini-Mental State Examination. Data are 
expressed as mean + standard deviation. For the genotype frequency values are 
expressed as number (%). 
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Molecular genetic analysis 
Genomic DNA was extracted from peripheral leukocytes by 
proteinase K digestion and standard phenol/ chlorophorm extraction 
procedure. The APOE gene polymorphisms were determined by Hha 
I restriction endonuclease digestion of PCR products, according to 
Hixson and Vernier [26]. 
 
Statistical analysis 
The data were analyzed by analysis of variance (ANOVA) followed 
when significant by an appropriate post hoc comparison test. 
Differences were considered significant when a p-value ≤ 0.05 was 
attained. 
 
RESULTS 
118 subjects were enrolled among those referring to the Department 
of Geriatric Medicine, S. Orsola Fatebenefratelli Hospital in Brescia, 
Italy. Control subjects and AD and MCI patients were comparable as 
far as age and gender distribution (see Table 1). The distribution of 
ε2/ε3/ε4 alleles of APOE was 0.022/0.733/0.244 in AD cases, and 
0.056/0.889/0.056 in control subjects; the frequency of the APOE ε4 
allele was, as expected, higher in AD population than in control 
subjects. MCI showed a distribution of ε2/ε3/ε4 alleles of APOE of 
0.071/0.786/0.143.  
Blood mononuclear cells derived from AD and MCI patients and 
healthy subjects were subjected to cytofluorimetric analysis using the 
conformational specific antibody, PAb240, which discriminates 
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unfolded p53 tertiary structure. We only analyzed this population, 
since we previously demonstrated by immunofluorescence staining 
the presence of false positive cells, identified as granulocytes, 
showing under fluorescence microscope, a light diffuse mostly non 
specific signal, compared to the strong positivity to PAb240 antibody 
in monocytes and lymphocytes [24]. A highly statistically significant 
difference was found in the percentage of PAb240 positive cells when 
comparing controls with patients affected by MCI or AD subjects 
(percent of PAb positive cells, mean ± SD; control subjects: 23.4 ± 
11.9; MCI: 30.6±10.7; AD: 35.1±11.3; MCI versus control P<0.01, 
AD versus control P<0.001) (Fig. 1). 
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Figure 1: p53 protein expression in blood cells from AD, MCI and non-AD 
patients. (A) Box plot reporting the amount of conformationally altered p53 (%) 
expressed in peripheral blood cells for each subject enrolled in this study. Patients 
are divided according to the diagnostic group. Tukey-Kramer Multiple Comparisons 
Test has been used for statistical analysis. **p<0.01, ***p<0.001 vs control. (B) 
Quantitative analysis of conformationally altered p53 expression after flow-
cytometric analysis. Panels a, b, c, d, e, f are histograms reporting the fluorescence 
due to conformationally altered p53 expression (FL-2) vs the number of reacting 
cells (events). For each histogram the correspondent statistical analysis is reported. 
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To better characterize the nature of this different expression among 
AD, MCI, and control subjects, we evaluated whether the expression 
of conformational mutant p53 showed a correlation with some 
parameters linked to AD. As previously reported [24], a statistically 
significant correlation was observed only when the expression of 
mutant conformational p53 and the age of both control subjects and 
AD patients were considered, thus confirming in another independent 
population that conformationally altered p53 is an age-dependent 
factor (data not shown). 
Focusing on MCI group (28 patients), we found that 8 of them 
expressed APOEε4 allele. In addition, measurement of the percentage 
of PBMC expressing unfolded p53 of MCI patients defined two well 
separated groups. The division in two groups was made considering 
one standard deviation over control mean (calculated reference value 
35.3%), consistently with other previous data from literature [27]. 
The first group (n = 20) had percentages of unfolded p53 values 
ranging from 19.5% to 29.1% and the other group (n = 8) expressed 
values ranging 38.2% to 60.3%. The latter was candidate at high risk 
to develop AD, according to our previous indications [13]. Thus, 
according to the predicted criteria, 16 patients (8 with APOEε4 and 8 
with high unfolded p53) were at high risk to develop AD. 
Interestingly, the follow-up of MCI patients at two years from 
recruitment revealed that 14 out of 28 MCI patients converted to AD 
(Fig. 2). Among these, six had high values of unfolded p53, three 
expressed APOEε4 variant, and one had both high unfolded p53 and 
APOEε4. Four of the novel AD diagnoses were not predicted either 
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by the APOE genotype or by p53 conformational state (Fig. 2A). 
Among the nonconverted group (14 patients), four expressed the ε4 
variant of APOE gene and only one had high unfolded p53 (Fig. 2B). 
Moreover, in the MCI converted group, the expression of 
conformational altered p53 was independent from distribution of ε4 
allele of APOE (Fig. 2). 
This is also consistent with our previous work [28], demonstrating 
that the presence of the ε4 allele of APOE does not influence the level 
of conformational mutant p53 expression. The combination of 
APOEε4 allele and unfolded p53 yielded a sensitivity of 71.4% and a 
specificity of 84%, comparable with data reported by Zetterberg et al. 
[29] on cerebrospinal fluid (CSF) biomarkers. 
 
 
 
 
Figure 2: Scheme of converted and not-converted MCI patients based on 
unfolded p53 analysis and APOEε4 genotype. Twenty-eight MCI (5 males and 23 
females) with a mean ± standard deviation age of 69 ± 12.4 and MMSE score of 
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27.3 ± 2 were examined. Cognitive status was quantified using the Mini Mental 
State Examination (MMSE). None of the subjects selected in this study was 
affected by neoplastic or autoimmune disease when the blood samples were taken. 
Patients were divided in three groups according to APOEε4 variant and high 
unfolded p53. Two years later, patients were re-evaluated and classified as 
converted and non-converted in AD (A, B). 
 
DISCUSSION 
Recent research suggested that onset of AD is commonly preceded by 
an interim phase known as MCI. Since MCI diagnosis may include 
patients in a transitional state between prodromal and full blown AD, 
it is considered a window of therapeutic opportunity for treating 
patients prior to symptom onset [3], even if the presently available 
treatments are mostly symptomatic.  
On the other hand, important new pharmacotherapeutic options will 
likely become available only over the next decade, considering the 
variety of drug targets and mechanisms of action identified and the 
total number of compounds under investigation [30]. In view of 
existing and emerging therapeutic compounds, there is increasing 
interest to develop techniques allowing an accurate detection of the 
earliest phase of the disease. The introduction of biological markers in 
the clinical management of AD will not only improve diagnosis 
relating to early detection of neuropathology with underlying 
molecular mechanisms but also provide tools for the assessment of 
objective treatment benefits. 
Measurement of p53 conformational status in blood cells has been 
found to discriminate AD cases from normal aging, Parkinson‟s 
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disease, and other dementias [24]. In particular, the measurement of 
conformationally altered p53 has been demonstrated to be highly 
sensitive mainly in young patients with a sensitivity of 90% in 
subjects below 70 years of age [24]. Since p53 conformational 
changes found in AD cells have been demonstrated to be independent 
of gene mutations [31], it is reasonable to wonder about the 
mechanism by which p53 changes its conformational state. This issue 
is actually under investigation in our laboratory. On the other hand, a 
pathogenic link between p53 conformational changes and AD was 
indirectly suggested by the effects of low soluble concentrations of 
amyloid-β (Aβ) on p53 tertiary structure in fibroblasts [32] and other 
cell lines [33]. It is noteworthy that Aβ and prooxidant conditions 
may induce conformational changes in p53. The effect itself of Aβ on 
p53 misfolding can be counteracted by vitamin E [33]. Indeed, pro-
oxidant conditions in MCI and AD patients [34] may have driven the 
observed changes in PBMC. In addition the possibility that the p53 
misfolding in MCI and AD patients reflects an overall propensity to 
protein misfolding cannot be ruled out. 
In this study, to assess whether p53 conformational changes are an 
early event in AD pathology, we followed up patients falling in the 
MCI category for two years. Analysis of unfolded p53 was performed 
at the beginning of the enrollment and was used to predict which 
subjects among MCI patients will progress to AD. The results 
obtained in the present study confirm and extend the previous 
observations on AD patients. Furthermore,we found that a  
cytofluorimetric approach for conformationally altered p53 protein 
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was able to predict progression to AD in a small cohort of preclinical 
patients with MCI two years before clinical diagnosis for AD was 
made. The rate of progression of MCI to AD was comparable with the 
mean reported in population studies [3,10]. In fact we found that 50% 
of MCI patients converted to AD after two years from the 
recruitment. The high expression of unfolded p53 may be considered 
as high risk factor for the conversion to AD (among 8 patients with 
elevated unfolded p53 seven converted). In fact, in the MCI converted 
group, 50% was predicted based on elevated levels of 
conformationally altered p53, whereas only 28% was predicted based 
on APOE status. Noteworthy, higher levels of mutant conformational 
p53 and APOEε4 appeared to be independent risk factors for AD even 
if numbers are small to be strong at this point. In line with our 
previous data [28], complexively the mutant conformational p53 may 
be considered as a marker useful in the ε4 negative younger patients 
(≤ 70 years). 
Interestingly enough, when we combined the data on p53 and 
APOEε4, we obtained a calculated sensitivity of 71.4% and a 
specificity of 84% for the predictive test. Intriguingly, this accuracy 
was comparable with data reported by Zetterberg et al. [29] on 
combined CSF biomarkers. 
The fact that p53 was able to identify only a subset of converting 
patients is consistent with the idea that single biomarkers may not 
have sufficient sensitivity to detect all cases of the disease or adequate 
specificity to distinguish one pathology fingerprint from other disease 
profiles. For this reason is important to identify a battery of 
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determinations to increase the accuracy of the diagnosis. In this 
context, several studies have showed that selected combinations of 
preclinical markers may predict this conversion [35–37]. The 
combined use of cognitive tests, APOE genotype and a 
neuroradiological technique has been proposed as the best option for 
prediction, showing an accuracy > 90% [38]. Other research groups 
focused on CSF, total-tau/Aβ1−42, and magnetic resonance imaging 
(MRI) biomarkers, such as hippocampal, entorhinal, and ventricular 
volumes and brain atrophy rates, finding that their combination 
provides better prediction than either source of data alone [39,40], 
with a diagnostic accuracy of 80–90%. However, it is difficult to 
prepare a patient for all these analyses and sequential studies appear 
difficult to perform, making routine testing not practical in elderly at-
risk patients. This emphasizes the need for simple not invasive tests, 
useful to provide biomarkers that can identify MCI patients declining 
to AD. Search of biomarkers in the blood compartment has seen the 
significant contribution of the groups directed by Wyss- Coray. They 
developed a proteomic analysis of 18 proteins in the plasma of 
patients able to predict with 90% accuracy the diagnosis of AD [41]; 
furthermore these 18 proteins showed a potential in identifying 
patients with MCI who progress to AD [42]. However, the proteomic 
approach lacks of the identification of posttranscriptional protein 
modifications deriving from biochemical and metabolic events linked 
to the development of the pathology. 
Here we found that high values of unfolded blood p53, which has 
been linked to AD pathology, may be considered as high risk factor 
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for the conversion to AD and, when associated with APOEε4 
genotype, it yielded sensitivity and specificity values comparable to 
those obtained by a combination of CSF biomarkers. 
We are aware that the sample size of our study is too small to reach a 
definitive conclusion and the definition of conformationally altered 
p53 as predictive signature for MCI to AD requires a further 
investigation in larger and independent populations of patients, which 
is at the moment under investigation. Anyway, we suggest that 
measurement of conformational p53 state can be useful as an easy 
accessible adjunctive diagnostic tool in identifying those in the at-risk 
group of MCI patients who progress to AD. 
Finally, it is important to underline that we cannot speculate at this 
time whether conformational altered p53 found in AD peripheral cells 
is also present in the brain of AD patients and the relevance of such 
impairment in terms of neuronal function. Studies in this direction are 
now in progress in our laboratory. There are, however, previous 
postmortem studies suggesting an involvement of p53 in degenerating 
neurons in AD. These include de la Monte and colleagues [43] 
showing increased p53 and Fas expression in specific populations of 
cortical neurons; Kitamura et al. [44] showing increased amount of 
p53 in temporal cortex, mainly localized in glial cells; and Seidl et al. 
[45] showing higher levels of p53 in frontal and temporal lobe from 
Down syndrome patients. On the other hand it is not known whether 
the increase in p53 observed in the quoted papers occurs in 
degenerating neurons and/or reflects the expression of a 
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conformational altered isoform of p53, as we detected in blood cells 
and fibroblasts from AD patients [24,31,32]. 
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Introduction 
Mild cognitive impairment (MCI) is a transitional state between 
normal cognitive functioning and dementia. The current clinical 
criteria are unable to accurately identify the risk group for the 
progression to Alzheimer‟s disease (AD). The interest in biomarkers 
able to support clinical approaches is growing. We recently 
demonstrated that the detection of unfolded p53 allows to predict 
progression to AD in preclinical patients with MCI two years before 
the clinical diagnosis of dementia was evident [1]. 
In this study we determined to confirm the prognostic ability of 
unfolded p53 as predictive signature from MCI to AD in a 
longitudinal study on an independent population of patients.  
We examined the expression of unfolded p53 in patients up to 70 
years with MCI in order to discriminate this population from aged-
matched control subjects and AD patients. MCI patients have been 
evaluated every six months for at least two visits from the beginning 
of the enrollment comparing the measurement of unfolded p53 with 
data from neuropsychological evaluation, objective and neurological 
examination, cognitive evaluation, laboratory and radiological (CT 
Scan and RMI) investigation. 
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Preliminary data 
Sixty-seven subjects were enrolled among those referring to the 
Institute „Fondazione Casimiro Mondino‟ in Pavia, Italy. In this study 
we analyzed data from a group of 24 control subjects, 28 MCI and 15 
AD patients comparable as far as age and gender distribution (see 
Table 1).  
 
 
 
Table 1: Demographic and clinical variables and genotype frequency of the 
APO-E alleles of all the subjects enrolled in the study. N: number; M: male; F: 
female; L.O.I.: length of illness; MMSE: Mini-Mental State Examination. Data are 
expressed as mean + standard deviation. For the genotype frequency values are 
expressed as number (%). 
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The protocol of the study, including the follow-up visits, was 
approved by the Ethical Committee and a written consent was 
obtained from all subjects or, where appropriate, their caregivers.  
All the subjects were examined by a senior neurologist and diagnosis 
of dementia was made according to DSM-IV and the NINCDS-
ADRDA criteria. All MCI subjects met the original Petersen/Mayo 
criteria for MCI [2, 3]. Dementia was diagnosed based upon 
interview, objective and neurological examination, cognitive 
evaluation, laboratory and radiological (CT Scan and RMI) 
investigation. Cognitive status was quantified using the Mini Mental 
State Examination (MMSE) and with a neuropsychological battery of 
tests assessing learning and episodic memory, speed and attention, 
language and visuo-spatial functions. Within each cognitive domain 
several aspects of function were assessed in order to obtain as 
complete picture as possible of the cognitive status of the subjects. 
Control subjects were individuals with no clinical signs of 
neurological or psychiatric diseases, mostly enrolled among spouses 
of the MCI and AD group of patients. None of the subjects selected in 
this study was affected by neoplastic or autoimmune disease when the 
blood samples were taken.  
On the basis of our previous results [1, 4], blood mononuclear cells 
derived from healthy subjects, MCI and AD patients were subjected 
to cytofluorimetric analysis using the conformational specific 
antibody, PAb240, which discriminates unfolded p53 tertiary 
structure. As previously reported, a statistically significant difference 
was found in the percentage of PAb240 positive cells when 
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comparing controls with patients affected by MCI or AD (percentage 
of PAb240 positive cells, mean + standard deviation (SD); control 
subjects: 28.6 ± 11.8; MCI: 38.4 ± 12.7; AD: 43.4 ± 18.8 MCI versus 
control P < 0.05, AD versus control P < 0.01). 
The measurement of the percentage of PBMC expressing unfolded 
p53 of MCI patients defined two well separated groups. The division 
in two groups was made considering one standard deviation over 
control mean (calculated reference value 40.4%), consistently with 
other previous data from literature [5]. 
The first group (n = 15) had percentages of unfolded p53 values 
ranging from 20% to 38% and the other group (n = 13) expressed 
values ranging 40% to 63.3%. The latter group, according to our 
original hypothesis, was candidate at high risk to develop AD. After a 
mean of 15 months from the recruitment, 7 out of 28 MCI patients 
converted to AD. Among these, four expressed APOEε4 variant, four 
presented MT atrophy on MRI and all of them were predicted by high 
levels of unfolded p53.  
Only a subset (7/13) of p53 identified at risk patients converted to 
AD. This is consistent with the idea that a single biomarker, such as 
unfolded p53, may not be sufficient to detect invariably converters 
versus non converters. For this reason is important to include a series 
of other biomarkers (i.e. the APOE gene polymorphisms, 
neuroimaging, neuropsychological battery of tests) to increase the 
accuracy of the diagnosis. 
However, we cannot rule out that probably the 6 MCI patients at high 
risk of conversion, which expressed elevated levels of unfolded p53, 
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will convert at two years follow-up according to the rate of 
progression to dementia documented in literature [2, 3].  
These results confirmed that the high expression of unfolded p53 may 
be considered as high risk factor for the conversion to AD and that it 
is important to identify a battery of determinations. 
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Chapter II 
 
Pathogenetic link between unfolded p53 and 
Alzheimer’s disease 
 
Introduction 
Being the center of a complex organism regulation p53 serves 
different activities to ensure genomic integrity in cells. 
p53 acts as enzyme, operating as exonuclease during DNA repair, as a 
regulatory protein in numerous signaling pathways and as 
transcription factor, which is the most studied and functionally 
significant activity of the protein [1]. In fact, p53 has a domain 
composition typical for transcription factor able to bind specific DNA 
sequences and to transactivate a number of genes, by inducing or 
repressing them [2]. 
p53 transcriptional activity depends mainly on post-translational 
modifications and protein/protein interactions that comprise a large 
network of covalent changes inducing characteristic modifications 
within the protein quantity, activity and ability to interact or cooperate 
with a variety of other proteins [3]. 
Another important mechanism that controls p53 transcriptional 
function is the conformational stability since p53 is an intrinsically 
unstable protein.  
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Rationale 
Our research group has demonstrated, both in fibroblasts and in blood 
mononuclear cells from aged controls and demented patients, that 
there is with aging an increase in the expression of an unfolded p53 
protein state which is more pronounced in AD patients and is not 
dependent on gene mutations [4, 5]. As a result of such 
conformational change, p53 partially loses its activity and shows a 
significant impairment in its DNA binding and transcriptional 
capacity when cells are exposed to a noxious stimulus [4]. This 
altered conformation can be due to a loss of zinc (Zn
2+
) ion in the core 
domain of the protein, that provides the basic scaffold for the DNA 
binding and which has been demonstrated to be crucial for the 
stabilization of p53 in the so called “wild-type” folded form, 
recognized by the antibody PAb1620. Exposure of wild-type p53 to 
metal chelators such as ethylenediaminetetraacetic acid (EDTA) or 
orthophenanthroline determines a rapid switch to the unfolded form 
positive to the antibody PAb240 [6]. Upon addiction of micromolar 
amounts of Zn
2+
, the protein undergoes a refolding to the native form 
and reacquires DNA-binding competence [6] (Figure 1). 
Trying to investigate the cause of this alteration we found that the 
exposure to nanomolar concentrations of the beta-amyloid peptide 1-
40 (Aβ 1-40) induced the expression of the unfolded p53 protein 
isoform in fibroblasts derived from non-AD subjects [7]. These data 
suggest that the tertiary structure of p53 and the sensitivity to p53-
dependent apoptosis is influenced by low concentrations of soluble 
Aβ.  
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Figure 1: Micromolar amounts of Zn
2+
 determines the protein refolding to the 
native wild-type conformation and the DNA-binding competence. 
 
On this basis, we assumed that low amounts of soluble Aβ induce 
early pathological changes at cellular level that may precede the 
amyloidogenic cascade and one of these changes is the induction of 
the unfolded state of p53, suggesting a role of the protein in the early 
pathogenesis of AD [7].  
Recent evidence shows that the homeodomain interacting protein 
kinase 2 (HIPK2) is an evolutionary conserved serine/threonine 
kinase whose activity is fundamental in maintaining wild-type p53 
function, thereby controlling the destiny of cells when exposed to 
DNA damaging agents [8]. Hence, conditions that induce HIPK2 
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deregulation may result in a dysfunctional response to stressors by 
affecting p53 activity.  
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ABSTRACT 
Homeodomain interacting protein kinase 2 (HIPK2) is an 
evolutionary conserved serine/threonine kinase whose activity is 
fundamental in maintaining wild-type p53 function, thereby 
controlling the destiny of cells when exposed to DNA damaging 
agents. We recently reported an altered conformational state of p53 in 
tissues from patients with Alzheimer‟s Disease (AD) that led to an 
impaired and dysfunctional response to stressors. 
Here we examined the molecular mechanisms underlying the 
impairment of p53 activity in two cellular models, HEK-293 cells 
overexpressing the amyloid precursor protein and fibroblasts from 
AD patients, starting from recent findings showing that p53 
conformation may be regulated by HIPK2. We demonstrated that 
beta-amyloid 1–40 induces HIPK2 degradation and alters HIPK2 
binding activity to DNA, in turn regulating the p53 conformational 
state and vulnerability to a noxious stimulus. Expression of HIPK2 
was analysed by western blot experiments, whereas HIPK2 DNA 
binding was examined by chromatin immunoprecipitation analysis. In 
particular, we evaluated the recruitment of HIPK2 onto some target 
promoters, including hypoxia inducible factor-1α and metallothionein 
2A. 
These results support the existence of a novel amyloid-based 
pathogenetic mechanism in AD potentially leading to the survival of 
injured dysfunctional cells. 
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INTRODUCTION 
The protein p53 responds to a variety of cellular stresses and may 
induce cell cycle arrest or apoptosis In fact, by differential activation 
of a large number of target genes and by mitochondrial functions, p53 
is able to sense the intensity of the damage and modulate biological 
responses that can range from transient growth arrest to permanent 
replicative senescence or apoptosis [1]. 
The induction of p53 transcriptional activity depends mainly on 
posttranslational modifications together with protein/protein 
interaction [2]. Another important mechanism that controls p53 
function is its conformational stability since p53 is an intrinsically 
unstable protein whose structure includes one zinc atom as an 
important co-factor for DNA-binding activity in vitro and in vivo 
[3,4]. An increased content of an unfolded p53 protein isoform [5–7] 
has been reported in numerous tumour cells where p53 harboured 
different gene point mutations. On the other hand, conformational 
changes of p53 towards unfolded isoforms are not only associated 
with gene mutations, but post transcriptional modifications can affect 
p53 tertiary structure. It is worth noting that in cellular models of 
Alzheimer‟s Disease (AD), p53 was found to be conformationally 
altered, making these cells less vulnerable to stressors or genotoxic 
insults [5–7]. When investigating the mechanism of this alteration, we 
found that the exposure to nanomolar concentrations of beta-amyloid 
(Aβ) 1-40 peptide was responsible for the increased content of 
unfolded p53 protein [8]. One of the activators that induces p53 
posttranslational modification and wild-type conformational stability 
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is homeodomain interacting protein kinase 2 (HIPK2), an 
evolutionary conserved serine/threonine kinase able to regulate gene 
expression by the phosphorylation of transcription factors and 
accessory components of the transcription machinery. HIPK2 is 
activated in response to DNA damaging agents or morphogenic 
signals, thus playing a key role in differentiation, development or 
apoptosis [for a review see refs 9 and 10]. HIPK2 interacts physically 
and functionally with p53 and specifically phosphorylates p53 at 
serine 46 (Ser46) in response to severe DNA damage, regulating p53-
induced apoptosis [11,12]. In addition, it has recently been shown that 
HIPK2 depletion results in p53 protein misfolding, changing the wild-
type conformation to a conformationally altered status with 
subsequent abolishment of wild type p53 DNA binding and 
transcriptional activity. This can be restored with zinc 
supplementation [13]. 
Our purpose was to evaluate whether the altered conformational state 
of p53, observed in AD cells, was dependent on an impaired HIPK2 
function and, by the use of two cellular models of AD, to define 
whether a deregulation of HIPK2 is involved in AD pathogenesis. 
Furthermore, since AD is characterized by an aberrant metabolism of 
the amyloid precursor protein (APP), in turn resulting in an aberrant 
production of Aβ peptides [14], our intent was to investigate the 
effect of Aβ peptides on HIPK2 expression and DNA-binding 
activity. The results presented here may define a hierarchical scale of 
events related to Aβ activities and eventually lead to a better 
understanding of AD pathogenesis. 
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MATERIALS AND METHODS 
Reagents and cell treatments 
All culture media, supplements and Foetal Bovine Serum (FBS) were 
obtained from Euroclone (Life Science Division, Milan, Italy). 
Electrophoresis reagents were obtained from Bio-Rad (Hercules, CA, 
USA). All other reagents were of the highest grade available and were 
purchased from Sigma Chemical Co. (St. Louis, MO, USA) unless 
otherwise indicated. Amyloid-β (Aβ) peptide 1-40 and Ab 40-1 
reverse peptide were solubilised in DMSO at the concentration of 100 
mM and frozen in stock aliquots that were diluted at the final 
concentration of 10 nM prior to use. For each experimental setting, 
one aliquot of the stock was thawed out and diluted at the final 
concentration of 10 nM to minimize peptide damage due to repeated 
freeze and thaw. The Aβ concentration was chosen following dose 
response experiments (data not shown) where maximal modulation of 
p53 structure and its transcriptional activity [5] was obtained at 10 
nM. All the experiments performed with Aβ were made in 1% of 
serum. Doxorubicin was solubilised in H2O at the concentration of 10 
mM and frozen in stock aliquots that were diluted to working 
concentration (3.4 mmol/L) in medium at the moment of use. Zinc 
Chloride (ZnCl2) was diluted into the cell medium at 100 mM 
concentration for 16 h. To test proteasome activity, 6 hours before the 
end of treatment MG132 (Calbiochem, San Diego, CA, USA) was 
added to the medium at the concentration of 10 mmol/L. 
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Cell cultures 
Skin Fibroblasts from two non-AD controls (2 females, mean age 
63.569.2 years) and two AD patients (1 female, 1 male, mean age 
66.0611.3 years) were selected from the cell lines present in our cell 
repository originally established in 1993 [33]. The diagnosis of 
probable AD was made according to the criteria developed by 
National Institute of Neurological and Communicative Disorders and 
Stroke (NINCDS) and the Alzheimer‟s Disease and Related Disorders 
Association (ADRDA). All AD patients presented a 1–4 year history 
of progressive cognitive impairment predominantly affecting 
memory. Non-AD patients were without established cognitive 
disorders. Neither AD nor non-AD patients presented neoplastic 
diseases at the time of tissue biopsy. All cell lines were frozen at 
passage 2–4 in a modified growth medium containing 20% foetal 
bovine serum and 10% dimethylsulfoxide. For the experiments, cell 
lines were simultaneously thawed and grown up to passages 7–10. 
Cells were cultured as previously described [21]. Each set of 
experiments was done using cells at the same passage (ranging from 7 
to 10), carefully matching AD and non-AD samples. Culture 
conditions were kept constant throughout the experiments. Human 
embryonic kidney (HEK) 293 cells from European Collection of Cell 
Cultures (ECACC No. 85120602) were cultured in Eagle‟s minimum 
essential medium containing 10% foetal bovine serum, glutamine (2 
mM), penicillin/streptomycin (2 mM), at 37uC in 5%CO2/95% air 
[5]. The HEK-293 cells stably transfected with APP751 were 
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obtained as previously described [5] and maintained in G418 at a final 
concentration of 400 mg/ml. 
 
Transfection, plasmids and Western immunoblotting 
Transient transfection was carried out using the N,N-bis-2-
hydroxyethyl)-2-amino-ethanesulphonic acid-buffered saline (BBS) 
version of the calcium phosphate procedure and the following 
plasmids were used: HIPK2-Flag [11] and HIPK2-K1182R (MDM2-
resistant) mutant [34]. Total cell extracts were prepared as previously 
described [20] and immunoblotting was performed with mouse 
monoclonal anti-Flag (Sigma Chemical Co., St. Louis, MO, USA) 
and mouse monoclonal anti-tubulin (Immunological Sciences, Rome, 
Italy). Immunoreactivity was detected by enhanced 
chemiluminescence kit (Amersham, Little Chalfont, UK). 
 
p53 conformational immunoprecipitation 
p53 conformational state was analyzed by immunoprecipitation as 
detailed previously [7]. Briefly, cells were lysed in 
immunoprecipitation buffer (10 mM Tris, pH 7.6; 140 mM NaCl; and 
0.5% NP40 including protease inhibitors); 100 mg of total cell 
extracts were used for immunoprecipitation experiments performed in 
a volume of 500 ml with 1 mg of the conformation-specific antibodies 
PAb1620 (wild-type specific) or PAb240 (mutant specific) 
(Neomarkers, CA, USA). Immunocomplexes were separated by 10% 
SDS-PAGE and immunoblotting was performed with rabbit antip53 
antibody (FL393) (Santa Cruz, CA, USA). Immunoreactivity was 
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detected with the ECL-chemiluminescence reaction kit (Amersham, 
Little Chalfont, UK). 
 
RNA extraction and reverse transcription-PCR (RT-PCR) 
Total RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA, 
USA) following the manufacturer‟s instructions. The first strand 
cDNA was synthesized by reverse-transcribing 5 mg of mRNA with 
Moloney murine leukaemia virus reverse transcriptase kit and random 
primers (Applied Biosystems, Foster City, CA, USA). 
Semiquantitative RT-PCR was carried out by using Hot-Master Taq 
(Eppendorf, Milan, Italy) with 2 ml cDNA reaction and genes specific 
oligonucleotides under conditions of linear amplification. DNA 
products were run on 2% agarose gel and visualized by ethidium 
bromide staining using UV light. Data presented are representative of 
at least three independent experiments. 
 
Chromatin immunoprecipitation (ChIP) analysis 
Chromatin immunoprecipitation (ChIP) analysis was carried out 
essentially as described [13]. Protein complexes were crosslinked to 
DNA in living cells by adding formaldehyde directly to the cell 
culture medium at 1% final concentration. Chromatin extracts 
containing DNA fragments with an average size of 500 bp were 
incubated overnight at 4°C with milk shaking using polyclonal anti-
HIPK2 antibody (Santa Cruz, CA, USA). DNAprotein complexes 
were recovered with protein G Agarose (Pierce, Rockford, IL, USA). 
Before use, protein G was blocked with 1 mg/ml sheared herring 
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sperm DNA and 1 mg/ml bovine serum albumin (BSA) overnight at 
4°C and then incubated with chromatin and antibodies for 3 hrs at 
4°C. PCR was performed using immunoprecipitated DNA and 
specific primers for human HIF1a and MT2A promoters [15,17]. 
Immunoprecipitation with non-specific immunoglobulins (No Ab) 
was performed as negative controls. PCR products were run on a 2% 
agarose gel and visualized with ethidium bromide staining using UV 
light. The amount of precipitated chromatin measured in each PCR 
was normalized with the amount of chromatin present in the input of 
each immunoprecipitation. 
 
Transactivation assay 
For transactivation assay HEK-293 and HEK-APP cells were 
transfected with the p53-target promoter AIP1-luciferase reporter 
plasmid (kindly provided by H. Arakawa, National Cancer Center, 
Tokyo, Japan), MT2A-luc (kindly provided by Jean-Mark Vanacker, 
UMR5242 CNRS/INRA/Universite´ Claude Bernard Lyon/ENS, 
Lyon, France) or HIF-1α-p800-luc (kindly provided by Carine 
Michiels, Laboratory of Biochemistry and Cellular Biology, FUNDP-
University of Namur, Belgium) reporter plasmids, by using the 
cationic polymer transfection reagent jetPEI (PolyPlus-transfection, 
Illkirch, France) according to the manufacturer‟s instructions. 
Twenty-four hours later the cells were incubated with 100 mM Zinc 
Chloride (ZnCl2) for 16 h and with 3.4 mM doxorubicin for 24 h 
before luciferase activity was assayed. Transfection efficiency was 
normalized with the use of a co-transfected pCMV β-galactosidase 
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plasmid (β-gal). Luciferase activity was assayed on whole cell extract 
and the luciferase values were normalized to β-gal activity and 
protein content. At least three independent experiments were 
performed in duplicate. 
 
Densitometry and statistics 
All the experiments, unless specified, were performed at least three 
times. 
Following acquisition of the Western blot image through an AGFA 
scanner and analysis by means of the Image 1.47 program (Wayne 
Rasband, NIH, Research Services Branch, NIMH, Bethesda, MD, 
USA), the relative densities of the bands were analyzed as described 
previously [35]. The data were analyzed by analysis of variance 
(ANOVA) followed when significant by an appropriate post hoc 
comparison test as indicated in figure legend. The reported data are 
expressed as means 6 SD of at least three independent experiments. A 
p value < 0.05 was considered statistically significant. 
 
RESULTS 
Aβ is responsible for HIPK2 deregulation 
We first investigated whether HIPK2 DNA-binding to target 
promoters was somehow compromised by nanomolar concentrations 
of soluble Aβ peptides. To this aim, we treated HEK-293 cells with 
soluble Aβ 1-40 at the concentration of 10 nM for 48 h. As we have 
previously reported, this enters the cells and induces conformational 
changes in p53 protein [5]. Subsequently chromatin 
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immunoprecipitation (ChIP) experiments were performed in order to 
evaluate the integrity of interaction between HIPK2 and the hypoxia 
inducible factor-1a (HIF-1α) promoter, as recently reported [15]. As 
shown in Figure 1a, HIPK2 binding to HIF-1α promoter was 
eliminated by Aβ 1-40 treatment, whereas treatment with the reverse 
peptide Aβ 40-1 failed to do so. We further evaluated Aβ 1-40-
induced HIPK2 downregulation and mRNA expression was assessed 
in HEK-293 cells after treatment with Aβ 1-40. As shown in Figure 
1b, the analysis of RT-PCR following normalization to GAPDH 
expression revealed that no differences in HIPK2 mRNA expression 
were observed when comparing treated to untreated HEK-293 cells. 
Next, HIPK2 protein expression was evaluated by Western 
immunoblotting. As shown in Figure 1c, Aβ 1-40 treatment reduced 
HIPK2 protein levels in HEK-293 cells, compared to vehicle or Aβ 
40-1 treatment. Cell treatment with proteasome inhibitor MG132 
strongly reduced Aβ 1-40-dependent HIPK2 down regulation, 
increasing HIPK2 protein levels to an even larger extent when 
compared to control cells (Figure 1c), suggesting that additional 
proteasomal degradation processes besides that induced by Aβ 1-40 
are likely involved in HIPK2 degradation. Then HEK-293 cells were 
transfected with HIPK2-Flag and the degradation-resistant HIPK2-
K1182R mutant expression vectors. Subsequently cells were treated 
with Aβ 1-40 or the reverse inactive Aβ 40-1 peptide. As shown in 
Figure 1d, HIPK2-Flag expression was down regulated by Aβ 1-40 
while the reverse peptide was not effective, as reported above for 
endogenous HIPK2 (Figure 1c); Aβ 1-40 did not affect the expression 
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of the K1182 mutant (Figure 1d). Altogether, these results show that 
nanomolar concentrations of soluble Aβ can impair HIPK2 binding to 
DNA, likely through activation of proteasomal degradation, as 
assessed by the use of the proteasome inhibitor MG132. 
 
 
 
Figure 1. Aβ is responsible for HIPK2 deregulation. (a) ChIP experiments were 
performed with anti-HIPK2 antibody on HEK-293 cells treated with 10 nM Aβ 1-40 
or Aβ 40-1 for 48 h. PCR analyses were performed on the immunoprecipitated 
DNA samples using specific primers for the human HIF-1α promoter. A sample 
representing linear amplification of the total input chromatin (Input) was included 
as control. Additional controls included immunoprecipitation performed with non-
specific immunoglobulins (no Ab). A representative experiment of three 
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independent ones was shown. (b) HIPK2 mRNA expression was determined in 
HEK-293 cells, treated with 10 nM Aβ 1-40 for 48 h, by reverse-transcriptase (RT)-
PCR. GAPDH was used as loading control. (c) Total cell extracts of HEK-293 cells 
treated with 10 nM Aβ 1-40 for 48 h in the absence or presence of 10 mmol/L 
MG132 for 6 h were analysed for HIPK2 expression. Anti-tubulin was used as 
protein loading control. (d) HEK-293 cells were transfected with HIPK2-Flag and 
the degradation-resistant HIPK2-K1182R mutant expression vector. After 
transfection, cells were trypsinized, replated in triplicate and treated with 10 nM Aβ 
1-40 or the reverse peptide Aβ 40-1 for 48 h. Total cell extracts were analysed by 
Western immunoblotting with anti-Flag antibody. Anti-tubulin was used as protein 
loading control. 
 
Endogenous products of APP metabolism negatively affect 
HIPK2/DNA binding activity 
To acquire more insight into the contribution of the different APP 
processing products to HIPK2 deregulation, we used HEK-293 cells 
stably transfected with wild type APP751 (HEK-APP) that express 
high levels of full length APP in comparison with HEK-293 cells [5]. 
In particular, HEK-APP cells produced and released elevated amounts 
of Aβ peptides (see Table 1), where Aβ 1-40 was the more abundant 
isoform (700 pg/mg protein in cellular extracts and 200 pg/mL in the 
conditioned medium after 48 hrs) than Aβ 1-42 (78 pg/mg in cellular 
extracts and 42 pg/mL in the conditioned medium after 48 hrs). In 
order to prevent amyloidogenic APP metabolism, HEK-APP cells 
were then treated with b secretase inhibitor (bSI); Aβ 1-40 and Aβ 1-
42 levels were then measured in both cellular extracts and medium 
after b secretase inhibition. As shown in Table 1, inhibition of APP 
amyloidogenic pathway induced by β secretase inhibitor prevented 
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the formation of Aβ 1-40 and Aβ 1-42 in both the cellular extract and 
in the medium. HIPK2 binding to HIF-1α promoter was then 
evaluated in HEK-293 cells and HEK-APP cells that were also treated 
with the bSI. As shown in Figure 2a (left panel), HIPK2 was easily 
detected in the HIF-1α promoter in HEK-293 control cells while the 
recruitment was abolished in HEK-APP cells. Beta-secretase inhibitor 
treatment enhanced HIPK2 recruitment onto HIF-1α promoter (Figure 
2a, left panel), strongly suggesting that APP amyloidogenic 
metabolites may indeed affect HIPK2 DNAbinding activity. We then 
tested the ability of the conditioned medium of HEK-APP cells to 
inhibit HIPK2 DNA-binding. To this aim, HEK-293 cells were 
cultured with conditioned medium of HEK-APP cells that, as shown 
in Figure 2a (right panel), abolished HIPK2 binding to HIF-1a 
promoter. In agreement with our hypothesis, β-secretase inhibitor 
treatment counteracted the APP-conditioned medium ability to inhibit 
HIPK2 binding to DNA and re-established HIPK2 recruitment onto 
HIF-1α promoter (Figure 2a, right panel). 
A mechanism through which HIPK2 deregulation may affect p53 
conformation could be through metallothionein 2A (MT2A). 
Metallothioneins can act as potent chelators in removing zinc from 
p53 in vitro and may modulate p53 transcriptional activity [16]. In 
particular, HIPK2 depletion has been observed to induce MT2A 
upregulation, whose inhibition by siRNA restored p53 wildtype 
conformation and transcriptional activity [17]. These findings suggest 
that HIPK2 plays a critical role in maintaining p53 wildtype 
conformation for DNA binding and transcriptional activity indirectly 
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through MT2A down regulation. Hence, we investigated whether 
HIPK2 activity to bind MT2A target promoter was somehow 
compromised in HEK-APP. As shown in Figure 2b (left panel), ChIP 
assay showed that the HIPK2 recruitment onto MT2A promoter was 
hampered in HEK-APP cells in comparison with HEK-293 control 
cells, whereas it was recovered by treatment with β secretase 
inhibitor. Furthermore, when HEK-293 cells were treated with 
conditioned medium of HEK-APP cells, we observed an elimination 
of HIPK2 binding to MT2A promoter (Figure 2b, right panel). 
Parallel to data on HIF-1α, β secretase inhibitor treatment re-
established HIPK2 recruitment onto MT2A promoter thus 
counteracting the APP-conditioned medium ability to affect HIPK2 
binding to DNA (Figure 2b, right panel). These data were supported 
by the increased HIF-1α-luc and MT2A-luc activities in HEK-APP 
cells compared to the HEK-293 counterparts (Figure 2c). In 
agreement, MT2A and HIF-1α mRNA were induced in HEK-APP 
compared to HEK-293 cells, although to a different extent (Figure 
2d). These data suggest that impaired HIPK2 binding to DNA in AD 
cells correlated with increased HIF-1α and MT2A expression.  
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Table 1. Levels of Aβ 1-40 and Aβ 1-42 after treatment with β secretase 
inhibitor. Levels of Aβ 1-40 and Aβ 1-42 peptides were measured with a 
commercial ELISA kit in the cellular extracts and conditioned media of HEK-APP 
cells untreated or treated with b secretase inhibitor at 1 mmol/L for 48 hours. 
Results are representative of at least three independent experiments 6 S.E.M. 
* p<0.001 βSI treatment vs corresponding control. # p<0.01 βSI treatment vs 
corresponding control. 
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Figure 2. Endogenous products of APP metabolism negatively affect HIPK2 
DNA-binding activity. (a) ChIP experiments were performed with anti-HIPK2 
antibody on HEK-293 and HEK-APP cells that were also treated with b-secretase 
inhibitor at 1 mmol/L for 48 h and on HEK-293 treated with conditioned medium 
from HEK-APP cells for 48 h in the absence or presence of b-secretase inhibitor; 
PCR analyses were performed on the immunoprecipitated DNA samples using 
specific primers for the human HIF-1α promoter as shown in Figure 1. (b) ChIP 
experiments were performer with anti-HIPK2 antibody on HEK-293 and HEK-APP 
cells that were also treated with b-secretase inhibitor at 1 mmol/L for 4 8h and on 
HEK-293 treated with conditioned medium from HEK-APP cells for 48 h in the 
absence or presence of b-secretase inhibitor; PCR analyses were performed on the 
immunoprecipitated DNA samples using specific primers for the MT2A promoter. 
(c) HEK-293 and HEK-APP cells were transfected with MT2A-luc and HIF-1α-luc 
reporter construct and luciferase activity was measured 36 h after transfection. 
Results normalized to b-galactosidase activity are presented as fold of induction of 
luciferase activity 6S.D. At least three independent experiments performed in 
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duplicate. * p,0.01 (Student t-test). (d) MT2A and HIF-1α mRNA expression was 
determined in HEK-APP compared to HEK-293 cells by reverse-transcriptase (RT)-
PCR. GAPDH was used as loading control. 
 
p53 transcriptional activity is restored by zinc 
Following the data on MT2A overexpression, we wanted to evaluate 
whether the p53 dysfunction, related to Aβ exposure in our 
experimental models, could be restored by zinc supplementation. 
Thus, p53 transcriptional activity was evaluated by luciferase assay of 
the p53AIP1-luc apoptotic promoter [18]. HEK-APP cells and the 
control counterparts were transiently transfected with the p53AIP1-
luc reporter plasmid and 24 hrs later treated with 3.4 mM 
doxorubicin, a cytotoxic agent able to induce DNA damage and 
apoptosis in a p53-dependent manner [19]. As shown in Figure 3a, 
p53AIP1-luciferase activity was induced by doxorubicin treatment in 
HEK-293 cells, whereas it was significantly impaired in HEK-APP 
cells. Zinc supplementation to HEK-APP cells restored endogenous 
p53 ability to activate p53AIP1-luciferase reporter in response to 
doxorubicin (Figure 3a), while it only slightly increased p53 
transcriptional activity in HEK-293 cells. Next, analysis of mRNA 
showed that the doxorubicininduced p53 apoptotic gene transcription 
(i.e., Bax gene) in HEK-293 cells was impaired after stable 
transfection of APP751 (HEKAPP) (Figure 3b, compare lane 4 vs 
lane 2). In agreement with our hypothesis, zinc supplementation to 
HEK-APP cells restored druginduced Bax transcription (Figure 3b, 
compare lane 4 vs lane 5). Finally, Western immunoblotting showed 
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doxorubicin-induced Bax expression in HEK-APP cells only after 
zinc supplementation (Figure 3c). These data suggest that the Aβ-
inhibited wild-type 53 apoptotic transcriptional activity, in response 
to drug, was reactivated by zinc. 
 
 
 
Figure 3. Zinc supplementation to HEK-APP restores p53 pro-apoptotic 
transcriptional activity. (a) HEK-293 and HEK-APP cells were transfected with 
p53AIP1-luc reporter construct and 24 h after transfection treated with doxorubicin 
(3.4 mM) and zinc (100 mM) for 24 h before luciferase activity was assayed. 
Results normalized to b-galactosidase activity are shown as relative luciferase 
activity 6S.D. At least three independent experiments performed in duplicate. * 
p<0.05 vs HEK-293 or HEK-APP; ** p<0.01 vs HEK-APP (Bonferroni Multiple 
Comparison test). (b) Bax mRNA expression was determined in HEK-APP 
compared to HEK-293 cells by reverse-transcriptase (RT)-PCR after treatment with 
doxorubicin (3.4 mM) and zinc (100 mM) for 24 h. GAPDH was used as loading 
control. (c) Total cell extracts of HEK-APP cells treated with doxorubicin (3.4 mM) 
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and zinc (100 mM) for 24 h were analysed for Bax and p53 expression. Protein 
loading control was shown as Ponceau staining. 
 
AD fibroblasts show conformationally altered p53 protein and a 
reduced HIPK2 DNA-binding activity that are restored by zinc  
The conformational status of p53 was analyzed in fibroblasts derived 
from AD and non-AD subjects by immunoprecipitation technique 
using two conformational-specific antibodies, PAb1620 and PAb240, 
which discriminate folded versus unfolded p53 
tertiary structure [16]. Fibroblasts from AD patients from our cell 
repository express high levels of unfolded p53, as shown by Uberti et 
al. [7] and replicated in the two representative cell lines used in the 
current experimental setting (Figure 4a). Zinc supplementation to AD 
fibroblasts strongly reduced p53 mutant-like conformation (Figure 4a, 
upper panel), as is also shown by quantitative analysis of p53 
immunoprecipitates (Figure 4a, lower panel). Analysis of mRNA 
showed that MT2A expression was upregulated in AD cells (Figure 
4b), suggesting that HIPK2 deregulation might be involved in p53 
misfolding in AD cells, likely through MT2A upregulation, as 
previously shown [17]. As on HEK-APP cells, we then investigated 
whether HIPK2 activity to bind target promoters was somehow 
compromised in AD fibroblasts. As shown in Figure 4c, ChIP assay 
showed that the HIPK2 recruitment onto HIF-1α promoter was 
present in fibroblasts from control subjects, whereas it was hampered 
in AD cells. Of note, zinc treatment to AD fibroblasts restored HIPK2 
binding activity to DNA, likely counteracting the proteasomal 
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degradation, as previously reported [20] and thus suggesting that zinc 
was able to affect the dual role of HIPK2 as DNA co-repressor and as 
p53 activator. 
 
 
 
Figure 4. Fibroblasts from Alzheimer patients show misfolded p53 with 
increased MT2A expression and reduced HIPK2 binding to DNA. (a, upper 
panel) Equal amounts of total cell extracts from fibroblasts derived from AD 
patients were treated with 100 mM zinc for 16 h and then immunoprecipitated with 
anti-p53 conformational antibodies, PAb1620 for wild-type conformation and 
Pab240 for mutant-like conformation. 
Immunoprecipitates were analysed by Western immunoblotting with the polyclonal 
anti-p53 antibody. A representative experiment of three independent ones was 
shown. (a, lower panel) Densitometric analysis of immunoprecipitated p53 as 
above, showing reduction of PAb240 mutantlike conformation after zinc treatment. 
*** p<0.0001 vs AD (Student t-test). (b) MT2A expression was determined in 
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fibroblasts derived from AD patients compared to non-AD patients by reverse-
transcriptase (RT)-PCR. GAPDH was used as loading control. (c) ChIP experiments 
were performed with anti-HIPK2 antibody on fibroblasts from AD and non-AD 
patients. PCR analyses were performed on the immunoprecipitated DNA samples 
using specific primers for the human HIF-1α promoter. A sample representing 
linear amplification of the total input chromatin (Input) was included as control. 
Additional controls included immunoprecipitation performed with non-specific 
immunoglobulins (no Ab). A representative experiment of three independent 
experiments was shown. Amplification of GAPDH promoter was used as control of 
HIPK2 binding specificity to the HIF-1α promoter. 
 
DISCUSSION 
For the first time, we can describe a link between Aβ, AD related 
conformationally altered p53 and HIPK2, a transcriptional co-
repressor and activator of p53 apoptotic function. We previously 
demonstrated the existence of an unfolded state of p53 protein in 
fibroblasts from AD patients that led to an impaired and dysfunctional 
response to stressor [6,21]. Here we examined the molecular 
mechanisms underlying the impairment of p53 activity in two cellular 
models, HEK-293 cells overexpressing the amyloid precursor protein 
and fibroblasts from AD patients, starting from recent findings 
showing that p53 conformation may be regulated by HIPK2 [13]. Our 
data suggest that Ab peptides may be responsible for HIPK2 
deregulation. This is supported by the observation that Ab peptides 
down-regulated HIPK2 expression via proteasomal degradation 
(Figure 1c and 1d) leading to HIPK2 disappearance from target 
promoters such as HIF-1α and MT2A (Figure 1a, 2a and 2b). In 
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agreement, HIF-1α and MT2A mRNA upregulation was found in 
HEK-APP cells that overexpress APP751 (Figure 2d). The induction 
of MT2A, depending on HIPK2 knockdown has been reported to be 
responsible for p53 misfolding and inhibition of p53 transcriptional 
activity [16]; therefore, the present data suggest that HIPK2 
deregulation in HEK-APP cells and fibroblasts from AD patients 
might be involved in p53 misfolding, most likely through MT2A 
upregulation. 
Attempting to better investigate the contribution of APP metabolic 
products in the modulation of HIPK2 expression and change in p53 
conformational state, we then used HEK cells with wild-type APP 
able to generate high levels of Aβ 1-40 and Aβ 1-42 both 
intracellularly and secreted in the medium, with Aβ 1-40 about 10 
times more abundant than Aβ 1-42 [5]. We found that reducing APP 
amyloidogenic metabolism by treating HEK-APP cells with a β-
secretase inhibitor prevented the deregulation of HIPK2 (Figure 2a, 
2b) and likely the generation of the unfolded p53 isoform. 
Interestingly, we previously demonstrated that asecretase inhibitor did 
not affect unfolded p53 isoform and did not modify the cellular 
response to doxorubicin [5]. It is worthy to note that the conditioned 
medium of HEK-APP cells was able to affect HEK-293 cells 
recapitulating the HEK-APP phenotype, at least in terms of HIPK2 
DNA-binding and altered p53 conformational changes. The Aβ 
peptides released in the media by HEK-APP appeared to trigger such 
effects. In fact, the conditioned media of HEK-APP cells pretreated 
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with β secretase inhibitor, were unable to inhibit HIPK2 binding to 
HIF-1α and MT2A promoters, in HEK-293 cells (Figure 2b). 
HIPK2 has been shown to be down-regulated during hypoxia by 
Siah2-induced proteasomal degradation [22]. Moreover, HIPK2 
impairment during hypoxia induces de-repression of target genes such 
as HIF-1α, and inhibition of p53 activity [20]. Zinc supplementation 
to hypoxia-treated cells restores HIPK2 stability and binding to HIF-
1α promoter, rescuing also the p53 apoptotic transcriptional activity 
[20]. Therefore, discovering the mechanisms of HIPK2 inhibition and 
the ways to manipulate HIPK2 activity is an interesting option to 
affect several biological pathways [23]. Here we showed a novel 
mechanism of HIPK2 down-regulation mediated by Aβ, likely 
through activation of proteasomal degradation. HIPK2 is an unstable 
protein that is degraded via the proteasome pathway induced by 
several E3 protein ligases [24], although the molecular mechanisms 
underlying HIPK2 proteasomal degradation in conditions related to 
Ab exposure deserve further studies. 
The deregulation of HIPK2 function was further confirmed in 
fibroblasts from sporadic AD subjects, an extra-neuronal model 
showing a number of abnormalities in metabolic and biochemical 
processes, with some of them mirroring events that occur in the AD 
brain [25]. We found that fibroblasts from AD patients are 
characterized by a decreased HIPK2 DNA-binding activity, besides 
showing a conformationally altered p53. Since one of the features that 
distinguishes AD from non-AD fibroblasts is a defective non-
amyloidogenic APP processing, likely favouring an aberrant Aβ 
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peptides production [26], these data suggest that this abnormality may 
be, at least in part, responsible for altered HIPK2 binding to 
promoters. HIPK2 is ubiquitously expressed and has been found in 
developing neurons [27]. HIPK2 overexpression suppresses Brn3a-
dependent transcription of brn3a, trkA and bcl-xL resulting in 
apoptotic cell death in cultured sensory neurons [27,28]. Moreover, 
HIPK2 is an important component in the TGFb signalling pathway 
that regulates the survival of midbrain dopamine neurons, as 
suggested by HIPK2 knock-out mice [28,29]. Interestingly, it has 
been recently shown that HIPK2 is required for the trakA to p75NTR 
transition that leads to increased generation of Aβ that accompanies 
aging [30], suggesting a regulatory loop that tends to inhibit HIPK2 
during  aging contributing to AD. 
The impairment of HIPK2 function, by shifting p53 protein structure 
from a wild-type to a conformationally altered phenotype, should 
increase the threshold to a noxious stimulus, as reported [13]. 
Therefore, we tested, in HEK-APP cells, whether the reduced efficacy 
of doxorubicin-induced apoptosis was due to an impairment of p53 
apoptotic activity. In agreement with our hypothesis, we found that 
these cells showed a reduced HIPK2 DNA binding activity and Bax 
transcription in response to doxorubicin that was rescued by zinc 
(Figure 3). Zinc has been reported to restore p53 function in HIPK2 
depleted cells [13,17]. The capability of zinc to act in cells is ascribed 
to the existence of zinc transporters, that are required to convey this 
ion across cellular membranes, since zinc is unable to passively 
diffuse across cell membranes [31]. The use of zinc for AD treatment 
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is controversial, since several recent works reported the capability of 
zinc to cause the precipitation of Aβ into nonfibrillar amorphous 
aggregates [32]. However, in our experiments we speculate that the 
capability of zinc supplementation to restore the Aβ 1-40-inhibited 
HIPK2 DNA-binding appears not to be associated to a metal ion-
induced precipitation of the synthetic peptide but rather to 
counteracting a degradation mechanism. This is supported by the 
observations in fibroblasts from AD patients, in which zinc treatment 
was able to rescue HIPK2 binding to its target promoters. However, 
we could also not exclude the hypothesis that zinc may be able to 
withdraw the synthetic peptide from cellular environment thus 
modulating its interaction. 
In summary, we hypothesize that low amounts of soluble Aβ, not 
resulting in cellular toxicity, may be responsible for important 
modulatory effects at cellular level before triggering the 
amyloidogenic cascade. For the first time we found that one of these 
modulatory effects may be the inhibition of HIPK2 activity, with 
MT2A upregulation, in turn responsible for the induction of an altered 
conformational state of p53. As a result of this conformational 
change, p53 lost its transcriptional activity and was unable to properly 
activate an apoptotic program when cells were exposed to a noxious 
stimulus. Altogether, Aβ-induced HIPK2 depletion and unfolded p53 
may contribute to AD pathogenesis leading to dysfunctional cells. 
The definition of this new target is useful to help characterize the 
hierarchical scale of events driven by beta-amyloid so as to better 
understand the pathogenesis of AD. Furthermore, the recognition of 
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HIPK2 as new target of the effect of Aβ could suggest a new putative 
functional biomarker useful in addressing new therapeutic strategies. 
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ABSTRACT 
p53 transcriptional activity depends mainly on posttranslational 
modifications and protein/protein interaction. Another important 
mechanism that controls p53 function is its conformational stability 
since p53 is an intrinsically unstable protein. An altered 
conformational state of p53, independent from point mutations, has 
been reported in tissues from patients with Alzheimer‟s disease (AD), 
leading to an impaired and dysfunctional response to stressors. Recent 
evidence shows that one of the activators that induces p53 
posttranslational modification and wild‐type conformational stability 
is homeodomain‐interacting protein kinase 2 (HIPK2). Hence, 
conditions that induce HIPK2 deregulation would result in a 
dysfunctional response to stressors by affecting p53 activity. 
Discovering the mechanisms of HIPK2 activation/inhibition and the 
ways to manipulate HIPK2 activity are an interesting option to affect 
several biological pathways, including those underlying AD. Soluble 
beta‐amyloid peptides have recently been involved in HIPK2 
degradation, in turn regulating the p53 conformational state and 
vulnerability to a noxious stimulus, before triggering the 
amyloidogenic cascade. Here we discuss about these findings and the 
potential relevance of HIPK2 as a target for AD and highlight the 
existence of a novel amyloidbased mechanism in AD potentially 
leading to the survival of injured dysfunctional cells. 
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INTRODUCTION 
Alzheimer‟s disease (AD) is a primary progressive neurodegenerative 
disease where the aberrant metabolism of the amyloid precursor 
protein (APP) and the production and deposition of beta-amyloid 
peptide (Aβ) are considered responsible for neuronal death [1]. A 
putative link between the tumor suppressor p53 and the perturbation 
of APP metabolism has been demonstrated. In particular, an altered 
protein conformational state of p53, independent from point 
mutations, has been reported in tissues from patients with AD that led 
to an impaired and dysfunctional response to stressors [2-4]. One of 
the activators that induces p53 posttranslational modification and 
wild-type conformational stability is homeodomain-interacting 
protein kinase 2 (HIPK2) [5]. Here we discuss about the potential 
relevance of the definition of HIPK2 as a target for AD and highlight 
the existence of a novel amyloid-based pathogenetic mechanism in 
AD involving HIPK2 and unfolded p53,  potentially leading to the 
survival of injured dysfunctional cells. 
 
Alzheimer’s disease and beta-amyloid 
Beta-amyloid in AD is the result of the proteolytic metabolism of 
APP, an integral cell membrane glycoprotein of 697-770 residues 
which is the substrate of three proteolytic enzymes in two alternative 
pathways mutually in equilibrium [6]. In the nonamyloidogenic 
pathway, a protease, named α-secretase, cleaves APP in the 
extracellular domain and releases the ectodomain of APP (soluble 
APPα) into the extracellular space, thus precluding Aβ formation. 
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Otherwise, in the amyloidogenic pathway, Aβ is formed following 
cleavage by β and γ secretases, that cleave the N and C terminus of 
Aβ, respectively (Figure 1). The two main isoforms found in AD 
brains are Aβ 1-40 and Aβ 1-42. Physiologically the 40-amino-acid 
long peptide is the most abundant form [7-9], since the concentration 
of secreted Aβ 1-42 is about 10% that of Aβ 1-40 [10]. For these 
reasons, Aβ1-40 and Aβ1-42 may have different biological actions 
[11] and the ratio of their production may be altered in pathological 
conditions, such as in familial AD [12]. 
Although the direct and the indirect neurotoxic role of Aβ are 
unchallenged (for an exhaustive review see [13]), recent findings 
suggest that the peptide may have so far unforeseen physiological 
roles [14]. Besides its presence in AD brains, experimental evidence 
indicated that Aβ peptides are produced constitutively by all cells, 
including neurons, and are found in the nM-pM range in the CSF of 
non-demented individuals [15] and in media from neuronal and non-
neuronal cell cultures [16, 17], thus suggesting that, as well as having 
a potential pathological role in AD, Aβ peptides under normal 
conditions may have a role in the regulation of physiological 
functions, consistent with their ubiquitous presence and normal 
synthesis. We will discuss here on how Aβ may have a role in the 
regulation of the function of p53. 
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Figure 1. APP metabolism: schematic representation of the non‐amyloidogenic 
and amyloidogenic pathway. Here the 770 residue APP processing is schematized, 
even if the 695 and 751 transmembrane forms of APP exist. In the 
non‐amyloidogenic pathway, α‐secretase cleaves APP in the extracellular domain 
and releases soluble APPα into the extracellular space. Following this cleavage, a 
second enzymatic product, the C‐terminal fragment (αCTF or C83), which can be a 
substrate for γ‐secretase, yields a non‐amyloidogenic 3 kDa fragment known as p3. 
In the amyloidogenic pathway Aβ is formed following cleavage by β and γ 
secretases, respectively. The cleavage of APP at the residue 1 of Aβ sequence 
results in a truncated form of sAPP (sAPPβ) and in a C‐terminal fragment of 12 
kDa (βCTF or C99). The final step in the amyloidogenic pathway is the cleavage of 
βCTF, to liberate Aβ by γ‐secretase. Furthermore, in both the amyloidogenic and 
non‐amyloidogenic pathways, the cleavage of C83 and C99 fragments by 
γ‐secretase also results in the generation of C‐terminal peptides of 57‐58 residues, 
referred as APP intracellular domain (AICD). 
105 
 
p53 function and its role in aging and neurodegeneration 
From its discovery in 1979 [18], p53 continues to fascinate scientists 
and it is still nowadays one of the most extensively studied protein. 
Such interest is due to the key role of p53 in the prevention of cancer 
so as to be defined the “guardian of the genome” [19]. However, 
activities of p53 might have a role not only in regulating cancer 
progression, but also in the control of other aspects of health and 
disease such as development, aging and metabolism [20]. p53 exerts 
its main biological role of tumor suppressor and master controller of 
the genomic integrity especially acting as transcription factor [21]. 
p53 oversees the correct implementation of processes and it 
intervenes only in case of dangerous deviations from the proper 
cellular activity. When the cell is exposed to critical conditions or 
undergoes damages p53 arbitrates cell faith [22]. Loss of p53 or 
deregulation of its activities leads not only to cancer but also to 
cardiovascular, metabolic diseases, neurodegeneration and to the 
process of aging, because of the great number of p53-regulated genes 
which underlie all these different biological events [23] (see Table 1). 
The very first signal which stimulates p53 activity is the DNA 
damage and various genotoxic insults that could constitute a danger to 
the genomic integrity of cells such as oxidative stress, DNA damage, 
hypoxia, oncogene activation, telomere erosion, changes in 
metabolism, unusual prolongation of some signaling pathways and 
local depletion of nutrients, among others [41]. Immediately after 
these damages p53 is the substrate of a great number of possible 
posttranslational modifications introduced by a variety of specific 
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enzyme systems [42]. These alterations comprise a large network of 
covalent changes inducing characteristic modifications within the 
protein quantity, activity and ability to interact or cooperate with a 
variety of other proteins [43]. The delicate balance between p53 
Structure and Activity Relationship (SAR) can be disrupted even by a 
single amino acid substitution within the DNA binding domain 
(DBD) which is sufficient to limit or abolish the capacity of p53 to 
direct sequence-specific transcriptional activity [44]. This is the case 
of the majority of human cancers in which missense mutations in the 
DBD result in an altered network which can affect the prognosis. 
Beside gene mutation, p53 activity could be impaired also as 
consequence to a conformational change. p53 may lose its 
transcriptional activity due to an unfolded tertiary structure which 
determines a reduction in its affinity for specific DNA target 
sequence. Recent observations confirm that p53 structure changes can 
play a central role in aging and in AD [45, 46]. 
Because of its role in establishing senescence and in determining 
organism aging when its activity is increased, p53 can promote 
selected aspects of the aging process. Different studies indicate a 
delicate balance between the tumor suppressive and age promoting 
functions of p53. In several mouse models and also from human 
population studies, alteration of p53 activity has been demonstrated to 
influence the comparison of premature/accelerate aging under some 
circumstances (such as stress) or otherwise induce tumor suppression 
[47-52]. Evidence in mice and humans suggest that p53 acts as a 
longevity-assurance gene, basically reducing the influence of 
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tumorigenesis [53, 54]. Our group has studied p53 in fibroblasts from 
aged controls and demented patients finding that with aging there is 
an increase in the expression of an unfolded protein state, which is 
more pronounced in AD patients and is not dependent on gene 
mutations [55]. 
As a result of such conformational change, p53 partially loses its 
activity and shows a significant impairment in its DNA binding and 
transcriptional capacity when cells are exposed to a noxious stimulus 
[55]. In fact, AD fibroblasts are less vulnerable to oxidative injury 
than fibroblasts from non-AD subjects to the point that 
conformationally altered p53 has been proposed as putative biomarker 
for early AD [55]. This altered conformation can be due to a loss of 
zinc (Zn2+) ion in the core domain of the protein, that provides the 
basic scaffold for the DNA binding and which has been demonstrated 
to be crucial for the stabilization of p53 in the so called “wild-type” 
folded form. Exposure of wild-type p53 (wt53) to metal chelators 
such as ethylenediaminetetraacetic acid (EDTA) or 
orthophenanthroline determines a rapid switch to the unfolded form 
positive to an antibody (clone PAb240), recognizing a primary 
epitope cryptic in wt53 [56]. 
Upon addiction of micromolar amounts of Zn2+, the protein 
undergoes a refolding to the native form and reacquires DNA-binding 
competence [56]. Trying to investigate the cause of this alteration we 
found that the exposure to nanomolar concentrations of the 
betaamyloid peptide 1-40 (Aβ 1-40) induced the expression of the 
unfolded p53 protein isoform in fibroblasts derived from non-AD 
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subjects [3]. These data suggested that the tertiary structure of p53 
and the sensitivity to p53-dependent apoptosis is influenced by low 
concentrations of soluble Aβ. On this basis, we assumed that low 
amounts of soluble Aβ induce early pathological changes at cellular 
level that may precede the amyloidogenic cascade and one of these 
changes is the induction of the unfolded state of p53, suggesting a 
role of the protein in the early pathogenesis of AD [3]. Recently, in 
cultured peripheral blood cells derived from AD patients we and 
others observed a detectable amount of unfolded p53, recognized with 
the antibody PAb240, which made these cells distinct from those of 
controls. We suggest that unfolded p53 could be used as a biomarker 
of the disease also in early stages [57, 58]. Zhou and collaborators 
speculate that unfolded p53 might be the responsible for the failure of 
G1/S transition checkpoint in AD lymphocytes, which is normally 
mediated by wt53, connecting unfolded p53 to a peripheral event 
associated to the disease. They suggest that the cause of p53 
conformational change could be oxidative stress, Aβ toxicity and the 
effects of oxygen free radicals [59]. This additional observation about 
the existence of an altered state of p53 at the peripheral level in 
subjects with AD reinforces the hypothesis that the protein can have a 
role in the pathogenesis of the neurodegenerative disease. However, 
further studies are needed to understand the causes of such 
conformational change and, as consequence, about how unfolded p53 
contributes to the progress of age and neurodegeneration.
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Table 1. p53 at the crossroad of complex networks of stress response pathways. Different intercellular and extracellular stresses result in 
cellular outcomes directly mediated by p53 activation. The activation of p53 passes through a variety of modifications that occur at the protein 
level; these post‐translational modifications are crucial in regulating p53 function. We summarize in the table p53 signalling transduction 
pathways resulting in activation of specific downstream gene targets, whose role is to drive cell destiny. 
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Misfolded p53 and the role of HIPK2 
Homeodomain-interacting protein kinase 2 (HIPK2) is a member of a 
novel family of nuclear serine/threonine kinases that localizes into the 
nuclear bodies and acts as co-repressor for several transcription 
factors [60]. Furthermore, one important function of HIPK2 is the 
apoptotic activation of p53 in response to genotoxic agents [5]. 
HIPK2 interacts physically and functionally with p53 phosphorylating 
it at Serine 46 (Ser46) for apoptotic activation (Table 1) [28-31]. 
HIPK2 interacts also with the acetyltransferase CREB binding protein 
(CBP) and co-localizes with CBP and p53 at promyelocytic leukemia 
nuclear bodies (PML-NBs); here HIPK2-mediated p53Ser46 
phosphorylation enhances CBP-mediated p53 acetylation at Lys382, 
potentiating the expression of pro-apoptotic target genes [28]. Thus, 
although Ser46 can be phosphorylated by additional kinase other than 
HIPK2, including ATM [61], DNA-dependent protein kinase (DNA-
PK) [62], protein kinase C δ (PKCδ) [63], and dual-specificity 
tyrosine-phosphorylation-regulated kinase 2 (DYRK2) [64], the fact 
that only HIPK2 can drive Lys382 acetylation renders this kinase a 
unique and complex regulator of p53 apoptotic function. Thus, in the 
absence of HIPK2, the lack of Lys382 acetylation strongly impairs 
p53 pro-apoptotic activation [65]. HIPK2 function is important for the 
p53 acetylation/deacetylation balance by regulating the activity of 
deacetylase Sirt1, through repression of NADPH oxidase 1 (Nox1) 
[66]. Thus, in the absence of HIPK2, oxygen reactive species (ROS) 
are induced in cancer cells, with activation of Nox1 and Sirt1 
activities that inhibit p53 apoptotic activity in response to DNA 
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damage [66]. The role of HIPK2 in p53 activation in cancer cells 
involves also wt53 protein conformation. In the absence of HIPK2, 
p53 acquires a misfolded conformation loosing DNA binding and 
transcriptional activities, depending on deregulation of 
metallothioneins and Zn2+ [67, 68]. Thus, Zn2+ supplementation to 
HIPK2 depleted cancer cells determines a regain of the wt53 protein 
conformation and restoration of DNA binding and transcriptional 
activities in response to genotoxic agents in vitro and in vivo [67]. 
Treatment of mice carrying tumors derived from HIPK2-depleted 
cells with a combination of Zn2+ and chemotherapeutic drug 
Adriamycin enhances growth suppression of such tumors in vivo [67]. 
From these data it appears that HIPK2 plays a major role in the 
regulation of p53 function through the switch between p53 dynamic 
conformational states, and that Zn2+ is a fundamental cofactor. The 
binding and exchange/transport of Zn2+, as well as of other heavy 
metals, such as cadmium or copper, are modulated by metallothionein 
(MT), a family of at least 10 highly conserved, low molecular weight 
cystein-rich metalloproteins [69]. The interest in MTs derives from 
their role as regulators of p53 folding and activity, since small amount 
of MTs can induce p53 activity regulating the folding of the DBD 
domain through Zn2+ modulation, whereas excess of MTs reduces 
p53 activity by exerting their Zn2+ chelator function [70, 71]. 
Furthermore, an increase of MTs expression also correlates with 
chemoresistance, increased cell proliferation, reduced apoptosis and 
inhibition of p53 activity in various human tumors [72]. In this 
regard, it has been shown that HIPK2 negatively regulates MT2A 
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gene, whose mRNA transcript isoform appears to be associated with 
cell proliferation in invasive ductal cancer tissues and that, on the 
contrary, HIPK2 depletion correlates with MT2A up-regulation in 
MCF7 breast cancer cells [68]. Moreover, MT2A depletion by siRNA 
(silencing RNA) in cells depleted of HIPK2, restores wt53 
conformation [68]. 
 
HIPK2 inactive/active switch in Alzheimer’s disease and the 
relevance of zinc supplementation 
Given the role of HIPK2 in maintaining wt53 conformation in tumor 
cells and the presence of an unfolded state of p53 in AD peripheral 
cells, the interest of a putative modulation of HIPK2 in AD type 
dementia has been investigated. As reported above, the exposure to 
nanomolar concentrations of Aβ led to an increased content of 
unfolded p53 protein in fibroblasts from AD patients, compared to 
control subjects [3]. Looking at the molecular mechanism of p53 
misfolding, a link among Aβ, p53 and HIPK2 in the neuropathology 
may be proposed [73]. Aβ has been hypothesized to be responsible 
for HIPK2 proteasomal degradation, in turn resulting in HIPK2 
nuclear disappearance from target promoters such as hypoxia 
inducible factor 1α (HIF-1α) [74] and MT2A [68], whose mRNA was 
found upregulated in cellular models of AD [73]. The induction of 
MT2A, depending on HIPK2 knockdown, has been reported to be 
responsible for p53 misfolding and inhibition of p53 transcriptional 
activity [68]. On this basis, we could speculate that, in AD, HIPK2 
deregulation might be involved in p53 misfolding, most likely 
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through MT2A upregulation. Data from literature point out that MTs 
play a very important role in controlling Zn2+ homeostasis. Increased 
MTs levels induce down-regulation of many biological functions 
related to Zn2+, such as metabolism, gene expression and signal 
transduction [75]. The MTs can serve as a source of Zn2+ and are 
considered also as strong antioxidants and protective factors against 
stress conditions [76]. MTs are highly expressed in both astrocytes 
and hippocampal neurons in the aging brain and are a key area of 
investigation for inflammation and modulation of Zn2+ availability in 
the aging brain [77]. Therefore these proteins are being intensively 
studied in the context of aging and longevity mechanisms [78]. 
During aging there is an increased expression of MTs mRNA but 
decreased levels are found in healthy centenarians, indicating a 
possible selection for survival of low expressors [79]. However the 
precise function of these proteins in aging is still debated, because 
their protective role could also be deleterious in the case of 
sequestration of Zn2+ as observed both in human aging and AD [73, 
80, 81]. The high MTs mRNA in lymphocytes from old people and 
Down syndrome subjects and the low MTs mRNA in lymphocytes 
from young adult and centenarians are a significant support to the 
idea of a pleiotropic role of MTs in aging [82]. Therefore, the role of 
HIPK2 in MT2A regulation could unveil interesting interplay 
between these molecules with p53 also in other chronic diseases such 
as AD. Taking into account MT2A upregulation dependent on HIPK2 
depletion, zinc supplementation to hypoxiatreated cancer cells 
reestablishes HIPK2 nuclear localization and DNA binding activity, 
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restoring p53 apoptotic function in response to anticancer drug [83]. 
Similarly, zinc-supplementation to AD cellular models restores 
HIPK2 DNA binding, p53 wild-type conformation and apoptotic 
activity in response to a genotoxic agent [73]. Hence, we could define 
that, in AD, HIPK2 plays a critical role in maintaining p53 wild-type 
conformation indirectly through MT2A down regulation, and that 
Zn2+ is a fundamental cofactor. On the basis of data here 
summarized, we speculate that soluble Aβ may be responsible for 
important modulatory effects at cellular level before triggering the 
amyloidogenic cascade. One of these modulatory effects may be the 
inhibition of HIPK2 activity, with MT2A upregulation, in turn 
responsible for the induction of an altered conformational state of 
p53. As a result of this conformational change, p53 loses its 
transcriptional activity and is unable to properly activate an apoptotic 
program when cells are exposed to a noxious stimulus. Altogether, 
Aβ-induces HIPK2 depletion and the consequent unfolded p53 may 
contribute to AD pathogenesis leading to dysfunctional cells (Figure 
2). 
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Figure 2. Working hypothesis for a putative link among p53 protein, soluble 
Aβ and HIPK2. The figure shows a novel mechanism of HIPK2 deregulation 
mediated by Aβ. HIPK2, when activated in response to DNA damaging agents, is 
able to interact physically and functionally with p53 and phosphorylate p53 at 
serine 46, thus regulating p53‐induced apoptosis. HIPK2 also acts as transcriptional 
corepressor and deregulates the promoter metallothionein 2A (MT2A). MT2A may 
regulate p53 activity inducing protein folding through zinc modulation. In the 
presence of soluble Aβ, HIPK2 expression and activity are inhibited through 
Aβ‐induced degradation via the proteasome system (panel A). HIPK2 deregulation 
results in the induction of MT2A (panel A), that exerts its Zn2+ chelator function. 
As a consequence, p53 protein misfolding (changing the wild‐type conformation to 
a conformationally altered status) with subsequent abolishment of wild type p53 
DNA binding and transcriptional activity occurs (panel A). Zinc supplementation 
counteracts Aβ effects on HIPK2 regulation (panel B). Zinc enters into cells 
through specific zinc transporters, that are required to convey this ion across cellular 
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membranes, since zinc is unable to passively diffuse across cell membranes. Zinc 
can directly restore p53 function (panel B). In addition, zinc can also affect HIPK2 
function, thus resulting in HIPK2 reactivation (panel B). As consequence, MT2A is 
deregulated and p53 conformational can switch to the wild‐type and transcriptional 
active form (panel B). 
 
CONCLUSIONS 
In humans, aging may be influenced by the balance of cell survival 
versus cell death, a decision at least in part regulated by checkpoints 
proteins, by preservation of DNA integrity and correct repair [84]. We 
focused mainly on one of such proteins, p53, recently shown to be 
involved in aging and AD [55, 57, 58]. A link between AD pathology 
and an unfolded state of p53 has been proposed, based on findings 
that with aging an increase of unfolded p53 occurs in healthy subjects 
and is peculiarly high in AD patients. By investigating what could be 
the contribution of a conformational change of p53 to AD 
pathogenesis, for the first time we define a hierarchical scale of events 
driven by Aβ: Aβ-induced HIPK2 depletion and unfolded p53 may 
contribute to AD pathogenesis leading to dysfunctional cells [73]. 
This observation is intriguing in light of recent data showing that p53 
suppresses cellular aging. In this context, despite the well-known 
capability of p53 to induce senescence, more recent evidence 
demonstrated that p53 can also act as a suppressor of cellular 
senescence while promoting cell cycle arrest [85]. This dual effect on 
senescence may be ascribed to the fact that p53 regulates cell growth 
and metabolic stress through different pathways [86]. One of these is 
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represented by mTOR pathway, which is strictly connected with 
organismal aging, as its inhibition may be one of the main 
mechanisms decreasing lifespan [87]. p53 is able to regulate activity 
of mTOR following DNA damage or oncogenic stress by activation 
of specific effectors (PTEN, AMP kinase and TSC-2), each of which 
signals to diminish the activity of mTOR, which is involved in 
senescent phenotype [85, 88]. By suppressing mTOR, p53 can 
suppress senescent phenotype, converting senescence into quiescence 
[89]. Furthermore, mTOR inhibition induces autophagy, thus 
resulting in the accumulation of protein aggregates, endoplasmic 
reticulum stress and mitochondrial dysfunction, each of which could 
promote senescence [86]. Thus, taking into account that with aging an 
increase of unfolded p53 occurs, the loss of wild-type p53 
conformation could free mTOR, thus inducing aging-associated 
abnormalities. 
Thirty years have passed since p53 discovery and in these decades a 
lot of information about its structure, functions and pathways has 
been achieved. In the fourth decade of p53 investigation the research 
community hopes to be able to get new drugs to affect p53 function to 
treat not only cancer but also important neurological conditions, such 
as AD. The recognition of HIPK2 as new target of the effect of Aβ 
could suggest a new putative functional biomarker useful in 
addressing new therapeutic strategies [90]. 
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